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To all kids with inflammatory bowel disease, and especially to those that made 
these studies possible by so graciously giving your time, your blood and your guts 
- rarely with a complaint, and almost always with a smile. 
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ABSTRACT 
Background 
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), 
are lifelong conditions characterized by abdominal pain, bloody diarrhea and fatigue. The 
incidence and prevalence are increasing worldwide, with approximately 10-20% of all IBD 
cases diagnosed during childhood. The etiology is considered multifactorial but is not 
completely understood. However, genetic susceptibility, environmental factors and disturbed 
immunological function appear to contribute to the development of IBD. The treatments of 
pediatric CD and UC are only in part the same. Unfortunately, we still frequently use high 
dosage of corticosteroids, and we do not practice personalized medicine because of a lack of 
knowledge about which treatment best suits the individual patient. In our ambition to better 
understand the pathophysiology of IBD and the mode of action of established therapies, as well 
as to determine new therapy strategies, we studied the clinical effect of Infliximab (IFX) in 
children on maintenance treatment and the therapeutic effect of granulocyte and monocyte 
apheresis (GMA) in children with newly onset IBD. In addition, children with CD were treated 
with exclusive enteral nutrition (EEN) as induction of remission therapy. Finally, we studied the 
immunological profile in blood at onset and in intestinal mucosa at onset and after GMA and 
EEN treatment. 
Methods and results 
We investigated the association between s-IFX trough levels and antibodies to IFX (measured 
with ELISA, enzyme-linked immunosorbent assay) to clinical indices and CRP, ESR, albumin 
and F-calprotectin in 45 children om maintenance IFX treatment. The mean s-IFX trough levels 
were significantly higher during remission than in active disease, correlating to the clinical 
indices, ESR, CRP and albumin. The development of antibodies to IFX strongly correlated to 
undetectable s-IFX and active disease (Paper 1). In paper II (pilot study), 12 children with 
newly IBD colitis received 10 sessions with GMA together with a low to moderate dose of 
mesalazine as induction of remission. A control colonoscopy (CC) was performed 12 to 16 
weeks post-treatment, in which the endoscopic Mayo score showed significant improvement in 
9/12 children (8/12 were in clinical remission). In seven of these children (paper V), the 
expressions of 14 cytokines were investigated (by real time polymerase chain reaction, PCR) in 
the intestinal mucosa at onset and after the combination therapy of GMA and mesalazine. 
Significant decreases were seen in CSF-2, TNF-α, IL-23α, IL-1β, IL-36γ, IL-10 and TGFβ1 
after treatment while significant decreases were observed in the clinical index and Mayo 
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Significant decreases were seen in CSF-2, TNF-α, IL-23α, IL-1β, IL-36γ, IL-10 and TGFβ1 
after treatment while significant decreases were observed in the clinical index and Mayo 
endoscopic score. Compared with the IBD patients, significantly lower levels of IL-12β and IL-
23α were found in the six non-IBD controls at onset. In paper III, we characterized the 
chemokine receptor landscape in 45 children (UC: n=16, CD: n=12 and healthy controls: n=17) 
using flow cytometry. By defining a diagnostic algorithm based on these markers, we could 
distinguish UC from CD in >92% of the studied children with newly onset IBD. In paper IV, 12 
children with newly onset IBD were treated with six weeks of EEN as induction of remission 
therapy. Eleven of the 12 patients successfully completed the treatment. A CC after completion 
of EEN showed significant decreases in endoscopic scoring (SES-CD) and 83% of the patients 
were in clinical remission. Additionally, in six of the children mucosal cytokines were measured 
by real time PCR at diagnosis and at CC. An overall decrease (though not statistically 
significant) in pro-inflammatory cytokines, as well as both decreases and increases in the 
regulatory cytokines, were seen after EEN therapy. 
Conclusions 
We conclude that an active approach is needed in the care of children with IBD to achieve and 
maintain remission. Our findings reveal that the children on IFX maintenance treatment were 
only in remission in 28% of the visits. The combination of GMA and mesalazine was found to 
be a safe and effective treatment in children with newly onset IBD. It seems plausible to 
speculate that the decreases in mucosal cytokines after the induction of remission may explain 
the good clinical result. Moreover, a change in the mucosal cytokine profile after induction of 
remission with EEN was observed. By investigating the chemokine receptors, we found a 
possible prognostic IBD marker, and by analyzing the cytokine profiles in mucosal biopsies, we 
have extended the knowledge of immunological phenotypes in children with IBD.  
Suggestions for the future 
Corticosteroid-free treatment alternatives must be explored and those currently in use must be 
optimized. To conclude, more and bigger studies are needed to explore the pathogenesis of IBD 
to determine new treatment alternatives. 
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  1 
INTRODUCTION 
My research field and clinical work focus on pediatric Crohn’s disease (CD) and ulcerative 
colitis (UC). CD and UC are the most common types of inflammatory bowel disease (IBD), and 
a sharp increase in the incidence have been seen during the last decades. IBD seems to have 
followed by humanity: in the ancient Chinese Yellow Emperor’s canon of internal medicine 
(722-721 BC), an illness is described as resembling UC with abdominal pain, diarrhea and 
rectal bleeding. In 1859, sir Samuel Wilks, an English physician, described IBD more than 70 
years before Dr Burrill Crohn published a paper on “regional ileitis” in 19321, 2.  
Childhood is a comparatively short period in an individual’s life cycle. During this extremely 
critical period, personality and social skills develop, school and avocations take time and energy 
and physiological and physical development start to mature. Unfortunately, this is not always 
easy for children with IBD. The course of the disease is quite unpredictable, with frequent flares 
and sometimes it appears the bathroom is visited more often than school, activities and friends. 
Now, we do not have the required knowledge to predict the prognosis of the patients. More 
knowledge about the pathogenesis and how different treatments work are desirable. A more 
personal designed medication is needed but currently our knowledge about which treatment 
suits which patient is incomplete. When we started this research project, I thought it was all 
about finding new strategies and results that would be applied to benefit patients in the 
treatment or diagnosis of IBD.   
This goal is still important, but I have realized that going through the PhD process is also a 
personal journey in which I have learned a lot about myself and others. 
Many things did not turn out exactly as planned. Sometimes the level of frustration reached 
quite high levels, and more than once I asked myself, why did I take this road. On the other 
hand, a successful research result can bring about incredible satisfaction and joy. Research itself 
is a dynamic process and many researchers are enthusiastic and dynamic people. I would like to 
share some of my reflections and experiences (both of the results and more practical matters) 
that I have made during this long and inspiring journey, which you will find in the reflection 
squares in the last part (discussion). 
Helena Rolandsdotter 
Stockholm 2017
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1 BACKGROUND 
 DEFINITIONS 
IBD is a group of inflammatory diseases of the colon and upper intestinal tract characterized by 
chronic intestinal inflammation. The disease is normally divided into the following conditions: 
CD: This condition may affect any part of the gastrointestinal (GI) tract from mouth to anus. 
The inflammation is transmural (extending through the intestinal wall) and often discontinuous 
and segmental. Extraintestinal manifestations involving joints, eyes, skin and liver may occur as 
well as intestinal complications such as fistulas, perianal abscesses and stenosis. 
UC:  This disorder affects only the rectum and colon. The inflammation involves the mucosa 
(the lining coat of the colon) and is continuous, but the extension differs from distinct proctitis 
to pan-colitis. It may also include extraintestinal symptoms from joint,  eyes, skin and liver. 
IBD unclassified (IBDU): A distinction cannot be made between CD or UC despite extensive 
investigations with upper and lower endoscopy, histopathology and examination of the ileum. 
CD and UC share several common symptoms, such as diarrhea, often with blood, abdominal pain 
and cramping, reduced appetite and nausea, as well as an overall impaired general condition. In 
CD, mouth ulcers, concomitant fever and fistulas may present. Growth  impairment is more usual 
in children with CD (reported in 10-20% at diagnosis) than in children with UC3-6. Gross bleeding 
and anemia at diagnosis are more often seen in UC patients than in patients with CD. Patients 
with IBD may also entail considerable mental suffering and anxiety compared with people 
without IBD7, 8. 
 
 EPIDEMIOLOGY   
The incidence and prevalence of IBD have steadily increased worldwide and has become a 
global emergence disease in the past decades, especially in developed countries, with the 
disease affecting about 1 in 200 people9. In a report on IBD incidence in Denmark between 
1980 and 2013, the incidence of CD increased from 5.2 per 100,000 to 9.1 per 100,000 while 
the incidence of UC increased from 10.7 per 100,000 to 18.6 per 100,000. The increase in CD 
was greatest in patients aged <15 years; the increase in UC was seen in patients >15 years of 
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age. Furthermore, the incidence rates for women were significantly higher in both UC and CD 
than for men10. Today, the overall prevalence of IBD in Sweden is approximately 0.65%11. 
Approximately 10-20% of all IBD cases are diagnosed during childhood12 and onset is most 
common in adolescence to young adulthood, with a peak at 15-29 years. However, several 
studies have reported a rise in early onset IBD (diagnosis at age <10 years)13-15. The incidence 
of pediatric IBD has increased sharply in recent decades, as is true for the whole Northern 
hemisphere11, 16-18.  
In Sweden, prevalence of pediatric IBD in 2010 was 75/100,000 (0.75 ‰ of all children in 
Sweden in 2010) 19. Figure 1 depicts the incidence rate from 2003 to 2013 by type of IBD, sex 
and age of onset20.  
 
Everhov et al. AP&T, 2017 
 
 PATHOPHYSIOLOGY 
The causes of IBD are not clear and considered multifactorial, which is because of inflammatory 
responses and genetic factors. In short, genetic susceptibility, environmental factors and disturbed 
immunological function appear to contribute to the development of IBD21. 
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1.3.1.1 Genetics in IBD 
201 susceptibility loci for IBD, mostly shared between CD and UC have hitherto been 
discovered22. However, many IBD loci are also implicated in other autoimmune-mediated 
disorders, most notably with ankylosing spondylitis and psoriasis 23. Many of the involved 
genes regulate the ability of intestinal intraepithelial cells (IECs) to insulate themselves from 
direct microbial contact, handle the stress of metabolic and environmental factors and encode 
for proteins involved in autophagy24. A strong genetic factor in the development of IBD has 
been refuted. First reported in twin-studies, the CD concordance rates were between 33 and 
50% in monozygotic twins and between 3 and 10% in dizygotic twins. Heredity seems to play a 
larger part in CD than in UC25, 26. A first-degree relative to a patient with IBD has a tenfold 
increased  risk of developing the same disease as the relative when compared with the general 
population27. 
 In the largest genotype association study to date, three loci (NOD2, MHC, MST1 3p21) 
represent different sub-phenotypes that could be characterized primarily by the disease location: 
ileal CD, colonic CD and UC. The authors suggest that this nomenclature should be used 
instead of CD and UC as currently defined28.  
1.3.1.2 Environmental factors 
Smoking and GI infections have the strongest29 relationship to environmental factors that may 
trigger the onset of  IBD30, 31. In CD, early tobacco use increases the risk for disease 
development; in UC, current smoking protects against the IBD. Both onset and disease activity 
may be linked to smoking cessation in UC patients32. Some GI infections seem to trigger IBD 
onset: both UC and CD occur after previous infections with Salmonella spp, Mycobacterium 
avium, Shigella spp and Campylobacter spp, suggesting there is an alteration in the gut flora 
that triggers the start of a chronic inflammation process, and the reverse; some report have 
shown that helminth infection during childhood seems to protect against IBD33-35. Infections 
with Clostridium difficile, a gram-positive, anaerobic, spore-forming bacillus, may also worsen 
the course of IBD36. 
Theories of other environmental factors that may influence the increasing incidence of IBD 
have been suggested in terms of a higher living standard, including better hygiene and 
sanitation, smaller families, less women breastfeeding, consumption of a western diet and 
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cleaner water. All these factors may contribute but none have shown, either alone or in 
combination, any convincing association with the augmented incidence of IBD30, 31. 
1.3.1.3 Immunological dysfunction (short version) 
Comprehensive knowledge of the immune system plays a crucial role in understanding the 
pathophysiology of IBD, including knowledge of the intestinal barrier, the innate immune 
system and the adaptive immune system. The first line of defense is the mucosal barrier, a thin 
sheet of mucus secreted mainly by goblet cells, which also synthesize antimicrobial peptides. In 
both UC and CD, this barrier is dysfunctional and shows increased permeability due to T cell-
mediated disruption of the tight junction protein and enteric neuron dysfunction30, 31, 37. The 
innate immune responses include monocytes, macrophages and dendritic cells (DCs) that 
increase in correlation with disease activity38. The innate immune cells present antigens to T 
and B cells that take part in the adaptive immune system and disturb the delicate balance 
between regulatory T cells and helper T cells30, 31.  
 PEDIATRIC IBD 
Children and youth often have more severe and more extensive disease than adults, with vast 
involvement and rapid early progression39 40, 41. The CD phenotype shows less isolated ileal 
disease compared with adults and is characterized by a pan-enteric phenotype. Eighty-two 
percent of children with UC have extensive disease as compared with 48 percent of the adult 
population39.  
A difficult complication of pediatric IBD is growth failure, which is more severe in CD than in 
UC. Several factors contribute, such as loss of appetite, protein loss due to mucosal 
inflammation, malabsortion due to an inflamed mucosa, ongoing inflammation followed by an 
increased nutritional need, and corticosteroid (CS) treatment that interferes with growth 
hormones42. Studies have shown an association between levels of circulating inflammatory 
cytokines (interleukin 6 [IL-6] and tumor necrosis factor alpha [TNF-α]) and reduced growth 
velocity and impaired body composition43. 
 
 DIAGNOSTIC WORK-UP 
A complete medical history, physical examination, laboratory testing that includes full blood 
count, erytrocyte sedimentation rate (ESR), C-reactive protein (CRP), albumin, liver function 
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tests, transglutaminase antibody, fecal calprotectin and stool cultures to exclude infectious 
diarrhea are needed to diagnose a child with suspect IBD. Additionally, all children with 
suspected IBD should undergo a gastro-duodenoscopy and ileocolonoscopy as well as small 
bowel imaging with magnetic resonance imaging (MRI) or ultrasound, according to 
the  European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) 
revised Porto criteria for the diagnosis of pediatric IBD from 201444. Thus, the diagnosis is 
made based on history, physical examination, biochemistry and macroscopic and histological 
findings from the gastro-colonoscopy.  
1.5.1 Endoscopy and histology in IBD  
All endoscopic procedures during childhood are done in general anesthesia. An upper 
endoscopy and ileocolonoscopy with multiple biopsies from the esophagus, corpus, antrum and 
the proximal and descending duodenum, ileum, caecum, ascending, transverse, descending and 
sigmoid colon and rectum are performed according to the European Crohn's and Colitis 
Organization (ECCO)/ESPGHAN guidelines for newly onset IBD41, 44. 
CD and UC may demonstrate different appearances of gastro-colonoscopy: patients with CD 
typically show segmental and deeper intestinal inflammation that can involve any part of the GI 
tract. Children with UC commonly show a superficial and continuous inflammation. Table 1 
shows endoscopic characteristics and Table 2 histologic characteristics of CD and UC. 
Table 1. Endoscopic characteristics of CD and UC 
CD 
Endoscopic characteristics 
UC 
Endoscopic characteristics 
Ulcers Ulcers 
Cobblestoning Erythema 
Skip lesions Loss of vascular pattern 
Strictures Granularity 
Fistulas Friability 
Segmental distribution Spontaneous bleeding 
Fissures, fistulas, abscesses Pseudopolyps 
 Continuous (proximal 
extension from rectum) 
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Table 2. Histologic characteristics of CD and UC 
CD 
Histological characteristics 
UC 
Histological characteristics 
Submucosal or transmural 
involvement 
Mucosal involvement 
Ulcers, crypt distortion Crypt distortion 
Crypt abscesses Crypt abscesses 
Granulomas Goblet cell depletion 
Focal changes (within 
biopsy) 
Continuous distribution 
Patchy distribution (between 
biopsies) 
 
 
 SCORING SYSTEMS  
Several scoring and classification systems have been developed for clinical use and research 
purposes. In clinical practice, scoring systems make it easier for the physician to evaluate the 
patient and in research different study results can be compared. Although, having a wide variety 
of scoring systems may be confusing. Not surprisingly, not all scoring systems are in use today 
in clinical practice. Pediatric gastroenterologists often use different scoring systems than 
gastroenterologists working exclusively with adult patients.  
1.6.1 Clinical scoring  
The Pediatric CD Activity Index (PCDAI) is widely used and has been found to be a reliable 
tool for intervention trials in CD45. The index describes four general dimensions during the last 
week: history, physical examination, growth parameters and common laboratory tests. Disease 
activity is as follows: <10 point = remission, 10–27.5 = mild disease, >27.5–37.5 = moderate 
disease and >37.5-100 = severe disease. A PCDAI decrease of ≥12.5 points reflects a clinically 
significant response to treatment46. Newer, shorter versions of the PCDAI have been 
constructed (weighted PCDAI, short PCDAI, abbreviated PCDAI and modified PCDAI). These 
newer versions are considered more feasible to use than the original version46. 
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The Pediatric UC Activity Index (PUCAI) is widely used to score patients in the everyday 
clinical setting, as well as for research purposes47. The answers reflect the status of the patient 
during the last two days and encompass abdominal pain, rectal bleeding, stool consistency, 
number of stools per 24 hours, nocturnal stools and activity level. A PUCAI <10 is interpreted 
as remission, 10-34 as mild disease, ≥35-64 as moderate disease and ≥65-85 as severe disease. 
A significant improvement is construed as a change in PUCAI of ≥35, moderate improvement 
≥20-34 and small improvement ≥10-1947. 
Other clinical CD scores currently used in adult gastroenterology are the CD Activity Index 
(CDAI)48  and the Harvey and Bradshaw’s Activity Index (HBI), which is a simpler version of 
the CDAI49. In UC, the Modified Truelove and Witt’s Severity Index50 and the Mayo score 
have been frequently used (Mayo including endoscopic findings and partial Mayo without 
endoscopic findings)51. 
 
1.6.2 Classification 
The most used phenotype classification in pediatric IBD, the Paris classification, is a 
development of the Montreal classification that had several weaknesses with respect to 
classification of children (change in disease location and behavior over time). It gives 
possibilities to find a genotype-phenotype association, which is of great value in research, but 
also makes it easier to follow the course of the patients in a structured manner (Table 3). 
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Table 3. The Paris classification of pediatric IBD describes the phenotype of both UC and CD. 
Ulcerative colitis E1 E2 E3 E4 
Location Ulcerative proctitis  Left-sided UC, 
distal to splenic 
flexure 
Extensive, hepatic 
flexure distally 
 
Pan-colitis, 
proximal to hepatic 
flexure 
Severity 0 Never severe  Defined as PUCAI  ≥65  
Severity 1 Ever severe Defined  as PUCAI  ≥ 65  
 
Crohn’s disease     
Age at diagnosis=A A1a 0-< 10 y A1b 10-<17y A2 17-40 y A3 >40 y 
Location=L L1: distal 1/3 ileum 
± limited cekal 
disease 
L2: colonic L3: ileocolonic L4: isolated upper 
disease* 
Behavior=B B1: non-stricturing, 
non-penetrating 
B2: structuring B3: penetrating B2B3: both 
structuring and 
penetrating disease 
Growth=G G1: growth delay G0= no evidence of growth delay  
Perianal disease=P     
*In the Paris classification system, L4 and L4a/L4b may coexist with L1, L2, l3. 
**L4a: upper disease proximal to ligament of Treitz, L4b: upper disease distal to ligament of Treitz and proximal to 
distal 1/3 ileum. 
 
1.6.3 Endoscopic scoring  
Why is a reliable endoscopic scoring system so important to achieve? Professor Marcus Neurath 
elegantly summarized this in the following comment: 
The structural basis of mucosal healing is an intact barrier function of the gut 
epithelium that prevents translocation of commensal bacteria into the mucosa and 
submucosa with subsequent immune cell activation. Thus, mucosal healing 
should be considered as an initial event in the suppression of inflammation of 
deeper layers of the bowel wall, rather than as a sign of complete healing of gut 
inflammation52. 
1.6.3.1 Crohn’s disease: endoscopic indices 
For CD, there are mainly two endoscopic indices in use. One index is the CD Endoscopic Index 
of Severity (CDEIS). Deep and superficial ulcerations for five segments and the presence or 
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absence of stenosis (ulcerated and non-ulcerated stenosis) are obtained to produce this validated 
scoring53. This scoring correlates well with the clinical scoring CDAI but is known to be 
complicated to use. The other index, the Simple Endoscopic Score (SES-CD), is also frequently 
used and correlates well with the CDEIS. It scores ulcer size, ulcerated surface, affected surface 
and luminal narrowing in five segments. The CD-SES is easier to use than the CDEIS. 
Regrettably, no endoscopic indices measure upper inflammation, which is not unusual in 
pediatric CD. 
1.6.3.2 Ulcerative colitis: endoscopic indices 
The modified Baron score, developed from the original Baron score (1964), describes the 
mucosa as normal, mild, moderate and severe51. The newer Ulcerative Colitis Endoscopic Index 
of Severity (UCEIS) is a validated scoring system comprising three components (vascular 
pattern, bleeding, erosions and ulcers), each with precise definitions and three or four levels of 
severity, yielding a 9-point scale scale54. 
The Mayo endoscopic score is a widely used three-point scale that has not yet been validated 
(Table 4)51.  
 
Table 4. Mayo ulcerative colitis endoscopic score. 
Endoscopic Mayo score Endoscopic findings 
Score 0 = remission Normal mucosa 
Score 1= mild disease Erythema, decreased vascular pattern, mild friability 
Score 2 = moderate disease Marked erythema, lack of vascular pattern, friability and erosions 
Score 3 = severe disease Spontaneous bleeding, ulceration 
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Table 4. Mayo ulcerative colitis endoscopic score. 
Endoscopic Mayo score Endoscopic findings 
Score 0 = remission Normal mucosa 
Score 1= mild disease Erythema, decreased vascular pattern, mild friability 
Score 2 = moderate disease Marked erythema, lack of vascular pattern, friability and erosions 
Score 3 = severe disease Spontaneous bleeding, ulceration 
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1.6.4 Histologic scoring 
In a recent meta-analysis of 15 studies (n=1573 patients), the predictive power of histology was 
analyzed. This report concluded that histologic remission correlates to less flares and that 
histologic remission was superior as a predictor of outcomes compared with endoscopic and 
clinical remission55.  
Nevertheless, another recent meta-analysis that evaluated the development and operating 
characteristics of histologic disease activity indices of UC found that none of the currently 
available histologic scoring indices have been fully validated56. The same condition prevails for 
CD, i.e. no fully validated histological scoring index is available. In a systemic review of 
evaluating available histological disease indices, the Nainia and Cortina Score was assessed for 
feasibility and found to be easily administered57, 58. 
That active disease reflects neutrophils in the crypt epithelium and crypt lumen (cryptitis and 
crypt abscesses) seems to be a generally agreed upon marker of disease activity, whereas other 
histological features are more variable across studies.59 Mild inflammation (close to remission) 
is characterized by the lack neutrophils but various degrees of chronic inflammation may 
persist. 
The Geboes score is a widely used instrument to measure disease activity60. This 
histopathologic scoring system uses a six-point grading system: architectural changes, chronic 
inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, 
crypt destruction and erosions or ulcerations. Each grade of the scoring system is divided into 
four subcategories. A simplified Geboes score has been developed because the original Geboes 
is somewhat complicated to use. Both the simplified and the original Geboes instruments have 
not been fully evaluated59. 
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Geboes score: different grades used to evaluate disease severity in UC. 
Grade 0 - Structural (architectural change)  
 0.0 No abnormality | 0.1 Mild abnormality | 0.2 Mild/moderate diffuse or multifocal abnormalities| 
 0.3 Severe diffuse or multifocal abnormalities   
Grade 1 - Chronic inflammatory infiltrate  
1.0 No increase | 1.1 Mild increase | 1.2 Moderate increase |1.3 Marked increase    
Grade 2- Lamina propria neutrophils and eosinophils   
2A Eosinophils 2A.0 No increase | 2A.1 Mild increase | 2A.2 Moderate increase | 2A.3 Marked increase     
2B Neutrophils 2B.0 None | 2B.1 Mild but unequivocal increase | 2B.2 Moderate increase | 2B.3 Marked increase    
Grade 3 - Neutrophils in epithelium   
 3.0 None | 3.1 < 5% crypts involved | 3.2 < 50% crypts involved | 3.3 ≥ 50% crypts involved   
Grade 4 - Crypt destruction   
 4.0 None 4.1 Probable—local excess of neutrophils in part of crypt| 4.2 Probable—marked attenuation| 4.3 Unequivocal crypt destruction        
Grade 5 - Erosion or ulceration   
 5.0 No erosion, ulceration, or granulation tissue | 5.1 Recovering epithelium adjacent inflammation | 5.2 Probable erosion/focally stripped | 
5.3 Unequivocal erosion | 5.4 Ulcer or granulation tissue    
 
Position of the neutrophils between the epithelial cells scored separately in grade 3 
 
 
 PEDIATRIC IBD TREATMENTS 
The main treatment goal for CD and UC is mucosal healing, which is normally followed by 
optimized growth, relief of symptoms and improved quality of life. Treatment is divided into 
remission and maintenance therapy: remission therapy aims to decrease the inflammatory 
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 PEDIATRIC IBD TREATMENTS 
The main treatment goal for CD and UC is mucosal healing, which is normally followed by 
optimized growth, relief of symptoms and improved quality of life. Treatment is divided into 
remission and maintenance therapy: remission therapy aims to decrease the inflammatory 
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burden while the aim of maintenance treatment is to prolong treatment response and delay the 
time to relapse. 
Today, we do not practice personalized treatment regimes because of a lack of knowledge about 
which treatment best suits the individual patient. Instead, we most often employ the step-up 
model of treatment for CD and UC, starting with a treatment that has been in use for a long time 
(most often 5-Aminosalicylates [5-ASA], CSs and EEN) and proceed with other more exclusive 
and expensive treatments when there is a lack or loss of response.  
The strategy of starting with more exclusive treatments as induction of remission (i.e. a top-
down approach) has been debated over the past decade61. According to a new pediatric 
American report, early anti-TNF treatment seemed to increase over time and was related to 
lower rates of CS use compared with the conventional approach62.  
Severe side effects are a difficult clinical problem for most medical treatments. This problem is 
particularly true for CSs. Thus, efficacy of treatment must always be weighed against harmful 
side effects. IBD in the pediatric population must be closely monitored by measuring f-
calprotectin, blood chemistry and validated scoring indexes (e.g., the PCDAI and PUCAI)45, 63. 
Surgery is often the treatment of last resort when there is no clinical response to other 
treatments, including intravenous CSs63. 
1.7.1 Aminosalicylates 
The 5-ASAs are released in different locations throughout the intestine: controlled release 
(Pentasa), pH dependent release (either pH 6 or 7) delivered distal of the distal ileum (Salofalk, 
Mesasal or Asacol) and azo-compounds that are delivered in the colon by bacterial cleavage 
(sulfasalazine)41. The mode of action of 5-ASA is not fully understood, but appears to act 
locally on colonic mucosa by activating a key receptor referred to as the Peroxisome 
proliferator-activated receptor (PPAR)-γ (a member of the steroid nuclear receptors), which is 
involved in apoptosis, cell proliferation, cytokine production and anti-tumorigenic effects64, 65. 
5-ASA given orally is a cornerstone in the treatment of mild extensive UC and is considered a 
safe treatment modality. It may also be given to patients with mild CD colitis as a first-line 
treatment but is not useful in upper and ileal CD. Isolated proctitis/left-sided colitis can be 
treated with suppository or enemas40, 41. An ongoing discussion concerns whether 5-ASA 
should be given in low or high dose, with some reports claiming that high dose or low dose 
regimes are equally effective as short-term treatment of active UC in children66, 67. 
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1.7.2 Corticosteroids 
CSs (also called glucocorticoids, corticosteroids or steroids) affect the innate and adaptive 
immune systems. The anti-inflammatory effect is mediated by four different main modes of 
action68. Through a mechanism termed transactivation, a cytoplasmic intracellular receptor for 
glucocorticosteroids affect a glucocorticoid-responsive element in the DNA, which induces the 
production of anti-inflammatory proteins69. Transactivation is also responsible to the CS side-
effects by an induction of gluconeogeneic enzymes68. The receptor also binds to 
glucocorticosteroids-responsive elements in the DNA and thereby inhibiting gene expression of 
IL-1 and IL-2. Transrepression involves the binding of the receptor complex to pro-
inflammatory transcription factors in the genome, thus preventing the transcription of activator 
protein 1 and NF-κβ70, and further, the receptor complex competitively inhibits co-activators in 
the nucleus followed by reduced expression of cytokines, like TNF-α and IFN-γ68. 
CSs are recommended for children with moderate to severe UC with systemic symptoms41 and 
up to 80% of the children with UC are treated with CS, mainly within 3 months of diagnosis. 
The short-term response rate varies from 50 to 90%67, 71, 72. Nevertheless, the correlation 
between clinical remission and endoscopic remission after cortisone treatment is low73. In 
children with CD, EEN is the first-line treatment, but CS therapy may be a viable alternative40. 
CSs could be taken orally, as suppository or enemas, or intravenously. Indeed, a corticosteroid-
sparing treatment is desired for children, largely because of the diversity of side effects: 
sleeping problems, euphoria, anxiety, nausea, excessive appetite followed by weight gain, 
stomach pain, acne, striae and growth impairment74. If CSs must be used, the treatment should 
be tapered as soon as possible because of the risk of these side effects41, 72. A difficult clinical 
problem is steroid dependency (defined as remission with CS but recurrence of symptoms when 
the dose is lowered, or if steroids cannot be stopped within 14-16 weeks). Indeed, the benefit of 
finding more CS free remission treatments for children and adolescents is of great importance.  
1.7.3 Exclusive enteral nutrition 
Children and youth with CD often present with growth impairment, both at onset and later in 
the disease course, which is due to GI inflammation, malnutrition and the use of CSs75. 
Therefore, it is important to consider other treatment modalities. In fact, the current standard 
treatment of induction of remission in pediatric patients with CD in Europe is 6-8 weeks with 
exclusive enteral nutrition (EEN)40. EEN consists of liquid formulas, either elemental 
 
 15 
1.7.2 Corticosteroids 
CSs (also called glucocorticoids, corticosteroids or steroids) affect the innate and adaptive 
immune systems. The anti-inflammatory effect is mediated by four different main modes of 
action68. Through a mechanism termed transactivation, a cytoplasmic intracellular receptor for 
glucocorticosteroids affect a glucocorticoid-responsive element in the DNA, which induces the 
production of anti-inflammatory proteins69. Transactivation is also responsible to the CS side-
effects by an induction of gluconeogeneic enzymes68. The receptor also binds to 
glucocorticosteroids-responsive elements in the DNA and thereby inhibiting gene expression of 
IL-1 and IL-2. Transrepression involves the binding of the receptor complex to pro-
inflammatory transcription factors in the genome, thus preventing the transcription of activator 
protein 1 and NF-κβ70, and further, the receptor complex competitively inhibits co-activators in 
the nucleus followed by reduced expression of cytokines, like TNF-α and IFN-γ68. 
CSs are recommended for children with moderate to severe UC with systemic symptoms41 and 
up to 80% of the children with UC are treated with CS, mainly within 3 months of diagnosis. 
The short-term response rate varies from 50 to 90%67, 71, 72. Nevertheless, the correlation 
between clinical remission and endoscopic remission after cortisone treatment is low73. In 
children with CD, EEN is the first-line treatment, but CS therapy may be a viable alternative40. 
CSs could be taken orally, as suppository or enemas, or intravenously. Indeed, a corticosteroid-
sparing treatment is desired for children, largely because of the diversity of side effects: 
sleeping problems, euphoria, anxiety, nausea, excessive appetite followed by weight gain, 
stomach pain, acne, striae and growth impairment74. If CSs must be used, the treatment should 
be tapered as soon as possible because of the risk of these side effects41, 72. A difficult clinical 
problem is steroid dependency (defined as remission with CS but recurrence of symptoms when 
the dose is lowered, or if steroids cannot be stopped within 14-16 weeks). Indeed, the benefit of 
finding more CS free remission treatments for children and adolescents is of great importance.  
1.7.3 Exclusive enteral nutrition 
Children and youth with CD often present with growth impairment, both at onset and later in 
the disease course, which is due to GI inflammation, malnutrition and the use of CSs75. 
Therefore, it is important to consider other treatment modalities. In fact, the current standard 
treatment of induction of remission in pediatric patients with CD in Europe is 6-8 weeks with 
exclusive enteral nutrition (EEN)40. EEN consists of liquid formulas, either elemental 
 16 
(formulations of amino acids), semi-elemental (formulations of amino acids and oligopeptides) 
or polymeric (whole protein formulas). This treatment has an overall clinical remission rate of 
73-80%; it effectively induces mucosal healing (MH) and is superior to CSs40, 76-79. It should be 
given to all children with luminal disease, including those with colonic involvement. EEN can 
be given orally or by a feeding tube40. The mechanism of action of EEN has not been 
elucidated, although different underlying mechanisms have been proposed, including correction 
of intestinal permeability, diminution of intestinal synthesis of inflammatory mediators via 
reduction in dietary fat, elimination of dietary antigen uptake and provision of important 
micronutrients to the diseased intestine. However, no strong evidence has been provided for any 
of these explanations. Children in remission following EEN have shown altered fecal microflora 
during and after EEN, suggesting that the change in gut microflora may induce remission80’ 81, 
82. One overriding benefit of EEN is that the often-malnourished child at CD onset not only 
obtains remission but also a positive nutritional status. Consequently, this treatment is favored 
before others. Body composition seems to improve with EEN, which is known to promote 
anabolism by reducing proteolysis and increasing protein synthesis75. However, many patients 
find it difficult to subsist on only a liquid diet without any other food for 6-8 weeks. This issue 
constitutes one of the main drawbacks of ENN treatment. A strict schedule must be drawn up by 
a dietician, and the physician and dietician must engage with the patient collaboratively for the 
child to continue the treatment.  
1.7.4 Thiopurines - Azathioprine and 6-Mercantopurine 
Thiopurines exert their anti-inflammatory effect through the formation of the active metabolite 
6-thioguanin-triphosphate (6-TGTP), which causes apoptosis of activated T-lymphocytes when 
administered in low dosage83. 
Small, retrospective studies84, 85 have shown that Azathioprines (AZAs) are effective and 
associated with prolonged maintenance of remission in CD and decreased rates of 
hospitalization, CS use and need of surgery. AZA and 6-MP are also used as a maintenance 
treatment in children with UC41. However, the results of different reports concerning the 
efficacy of thiopurines are contradictory. In a review that consisted of 13 randomized trials with 
1211 adult CD patients, AZA and 6-MP were found to be no more effective than placebo for 
induction of remission. However, patients on thiopurines could reduce the consumption of 
CSs86. Thiopurines are associated with malignancies and even if the total risk is low, a fourfold 
risk of lymphomas (notably in males) and in non-melanoma skin cancers in individuals ˂50 
years of age has been shown, and thiopurines augments the risk for the much-feared 
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hepatosplenic T-cells lymphoma87-89. Thiopurins is considered to reduce the risk of 
development of antibodies to Infliximab (ATI) and is therefore often used as a concurrent 
treatment to IFX during the first six month of Infliximab treatment (when the risk is considered 
high), but even here the reports are contradictive90-92. 
 
1.7.5 Anti-TNF-alpha treatment (infliximab and adalimumab) 
Infliximab (IFX, Remicade®) is a chimeric monoclonal IgG₁ antibody against TNF-α, an 
important pro-inflammatory cytokine that takes part in intestinal inflammation. Another TNF-α 
inhibitor is Adalimumab, a human antibody monoclonal drug used against IBD. These drugs are 
effective in inducing remission in both CD and UC. Moreover, they are sometimes used as a 
remission therapy, but mostly as a maintenance treatment for patients with severe IBD, 
especially effective early (</=3 month after diagnosis)in the disease course 90, 93. As 
recommended by the ESPGHAN/ECCO guidelines, anti-TNF treatment is indicated for patients 
with luminal disease despite optimal immuno-modulators, for children with active steroid-
refractory disease and for Crohn’s patients with active perianal fistulizing disease40. One study 
showed that IFX maintenance therapy was effective, being associated with prolonged CS 
withdrawal over a 3-year period in children with CD94. A new report, evaluating the occurrence 
of suboptimal IFX therapy in adult patients with IBD, showed that a majority of the patients 
(64% of UC and 58% of CD) had at least one indicator of suboptimal therapy (dose escalation, 
discontinuation, switching, non-biologic therapy escalation or surgery)95. Anti-TNF treatment 
has big advantages, but also some difficulties, except from the expense. Serious infections; 
sepsis, meningitis, abscesses, pneumonia, and herpes zoster, were seen in 33% of the patients in 
pediatric studies in which infections had occurred96. Other malignancies or Hemophagocytic 
Lymphohistiocytosis (HLH) are not associated with anti-TNF treatment in children according to 
a new study from 201797. 
Because IFX is biologically active, the drug is sometimes difficult to control. To maintain 
satisfactory levels of IFX in the circulation, serum trough levels should be followed (trough 
level refers to the concentration of a drug in the circulation just before the next 
administration)90, 98-100. If the s-IFX trough level is low, the anti-TNF dosage and/or IFX 
infusion intervals should be adjusted40. Loss of response can occur because of antibodies against 
IFX and because the inflammatory burden is very extensive90, 101. ATI can also produce acute 
infusion reactions and delayed-type hypersensitivity reactions40. Most studies on IFX trough 
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levels and ATI have been performed in adult IBD patients, and the pediatric studies on IFX are 
quite few in small study populations. 
1.7.6 Granulocyte monocyte apheresis 
Granulocyte and monocyte apheresis (GMA) is a device for selective depletion of the innate 
immune cells and can be used as treatment for both UC and CD. It contains acetate cellulose 
beads that attract and remove the Fc-ɣ receptors of activated leukocytes (granulocytes and 
monocytes) with a granulocyte adsorption ability over 2.18 x 10⁹ cells during one GMA 
session102-104. These immune cells are important producers of large numbers of pro-
inflammatory cytokines, including TNF-α, IL-1, IL-6 and IL-8. Accordingly, by reducing the 
activated leukocytes, the number of cytokines is reduced. Additionally, it reduces L-selectin and 
the chemokine receptor CXCR3, which mediates migration of leukocytes from blood into the 
inflamed intestinal tissue105. 
The GMA method uses intravenous access at two sites. The patient’s venous blood passes 
through the column and returns to the patient via the second venipuncture in the opposite arm. 
The flow rate is 30 ml/min and the treatment session lasts approximately 60 minutes.  
In children, it is traditionally used as last resort treatment. Reports show that the effect on 
remission is best in steroid-naïve patients and early in the course of the disease106, 107. Some 
studies suggest that more intense treatment (two to three sessions a week instead of the 
conventional once a week) is more effective in inducing remission108, 109.  
A Japanese study of 40 adult UC patients compared GMA treatment in combination with CSs 
vs. CS treatment alone. The patients were followed for 5 years. The study showed that 
concomitant GMA treatment significantly reduced the amount of CSs needed compared with 
corticosteroid treatment alone110. Only a few previous reports are published considered GMA in 
children.  
 
 MICROFLORA 
Gut microbiota refers to the bacteria, fungi, viruses, protozoa and archaea that inhabit the gut. 
The gut is the most heavily colonized organ, harboring over 70% of the microbes in the human 
body111.  Over 50 phyla have been described to inhibit the gut but the most predominant phyla 
of bacteria are Bacteroides and Firmicutes, which are considered strict anaerobes.112 
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 MICROFLORA 
Gut microbiota refers to the bacteria, fungi, viruses, protozoa and archaea that inhabit the gut. 
The gut is the most heavily colonized organ, harboring over 70% of the microbes in the human 
body111.  Over 50 phyla have been described to inhibit the gut but the most predominant phyla 
of bacteria are Bacteroides and Firmicutes, which are considered strict anaerobes.112 
  19 
The commensals (the beneficial bacterial population in the gut, also termed the normal 
microbial flora) aid in nutrient metabolism, prevent colonization of pathogenic microorganisms 
and help maintain healthy intestinal barrier function. The immune system seems to have 
evolved in coexistence with the commensals and together they defend against invasive 
pathological microbes111. Intestinal colonization starts immediately at birth when the young 
infant is exposed to various bacteria in the birth canal. Babies delivered by caesarian section 
exhibit a different gut flora than vaginally delivered babies113. It is presumed that the initial 
colonization shapes the composition of the gut microbiota, which is relatively stable after 1 year 
of age and resembles that of a young adult114. 
There are large inter-individual differences in gut flora. The mother’s gut flora composition is 
known to have the greatest impact on the child’s developing gut flora, but some obesity studies 
have shown that food may alter the composition of gut microbiota.115 
An imbalance in the composition of the intestinal bacterial, i.e. symbiosis, is most likely 
involved in the pathogenesis of IBD. In genome-wide association studies (GWAS), epigenetic 
findings and other genetic analyses have revealed links between changes in the intestinal 
microbiota and an improper immune response in IBD patients. This improper response is 
probably due to differences in the gut microbiota and altered bacterial function116. A Swedish 
twin study showed that gut microbial composition seems to be determined by genetics and 
environmental exposure in childhood. The Swedish study also showed that CD is associated 
with subsequent changes in the intestinal microbiota117. With new advanced biotechnology that 
includes modern sequencing and computer analysis methods, it is possible to investigate the 
microbial composition and characteristics of the bacteria.  
 THE HEALTHY INTESTINAL IMMUNE SYSTEM 
An intact immune system protects against uncontrolled and ongoing inflammation when 
confronted with the high antigen load that we are exposed to, both by food and the microbiota. 
The immune system is divided into the innate immune system and the adaptive (acquired) 
immune system, representing different layers of function as well as evolutionary origin118. The 
innate immune system includes monocytes, which develop to macrophages, dendritic cells 
(DC), neutrophils, eosinophils, basophils and natural killer cells (NKCs), the complement 
system and the cytokines and the recently discovered innate lymphoid cells. The innate immune 
response is initiated when pattern recognition receptors ([PRRs] and toll-like receptors ([TLRs]) 
on the cell surface and NOD-like receptors in the cytoplasm recognize microbial antigens119. 
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Innate immunity is present at birth and provides an immediate response to foreign invaders. 
Unlike the adaptive immunity, no specific antigen is remembered and no protection against 
future infection and invasion is provided.  
The adaptive immune system is not present at birth but develops as the immune system meets 
foreign antigens, adapts and remembers. T and B lymphocytes are responsible for acquired 
immunity; the immune response begins when antibodies produced by B lymphocytes encounter 
an antigen and the cytokines and the complement system enhances the ability of the antibodies 
to clear microbes and damaged cells from an organism. 
1.9.1 Intestinal microbiota and oral tolerance 
Immune homoeostasis refers to the highly complex interactions between inflammation and 
immunogenic tolerance to maintain balance in the immune system. This process starts in the 
healthy gut with oral tolerance, which is closely tied to the commensals. In the newborn baby, 
the gut flora is sterile (in utero the milieu is free of microorganisms) but colonization with 
commensals starts during birth, with aerobic species dominating at first, followed by 
anaerobes120. During this early microbial colonization, the mucosal immune system matures. 
Oral tolerance is a very important maturity function of the intestinal immune system exerted by 
the commensal bacteria that modulate the gene expression linked to crucial functions: xenobic 
metabolism (metabolism of toxins and drugs), mucosal barrier strengthening, nutrient 
absorption, intestinal maturation and angiogenesis121. The mechanisms for its establishment and 
maintenance are incompletely understood. 
1.9.2 Epithelial barrier 
In the intestinal immune system, first-line defense is represented by the epithelial barrier with an 
intestinal epithelium built up by one layer of cells, with interspersed, mucin-secreting Goblet 
cells. Figure 2. The mucus layer harbors commensals and is covered with secretory IgA and a 
glycocalyx (a coat of glycolipids, glycoproteins that contribute to cell-cell recognition, 
communication and intercellular adhesion)120.  Paneth cells are a specialized type of cells in the 
small intestine and produce various antimicrobial proteins, comparable with a broad-spectrum 
antibiotic against both gram positive (gram+) and gram negative (gram-) bacteria. They also 
seem to have an important role by secreting factors that help in the regulation of the epithelial 
stem- and progenitor cell who replenish the epithelial cells in the small intestine122 . The Paneth 
cells secret the antimicrobial protein α-defensin (small cysteine-rich cationic proteins). White 
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blood cells and mucosal epithelial cells in entire GI tract secret β-defensins, another 
antimicrobialprotein. The defensins exert their effect through lysate bacterial membranes with 
their amphipathic properties123, 124. 
1.9.3 Antigen recognition and immune regulation 
The luminal epithelium expresses PRRs who recognize several microbial components or 
microbe-associated molecular patterns: lipopolysaccharides, peptidoglycans, lipoteichoic acid 
and single stranded and double stranded RNA and methylated DNA that are unique to 
microbes. One important PRR group in mammals is the TLRs that are capable of recognizing 
most molecular patterns of the microbes120. TLRs trigger both innate and adaptive responses to 
microbes initiating an intracellular signaling process that results in a cytokine cascade leading to 
inflammation125. When antigen-presenting cells (APCs) encounter peptidoglycans (exposed on 
the surface in some microbes), cytosolic NOD1 and NOD2 proteins are expressed, whereby 
pro-inflammatory cytokines are released and further contribute to the innate immune 
response126’127. Conversely, TLRs have been shown to contribute to intestinal homeostasis 
when not triggered by pathogens128, 129 
1.9.4 Dendritic and lymphoid cells 
Many types of immune cell are found in the mucosa, including T cells, B cells, granulocytes 
and NKCs. The microfold cells (M cells) in the villi function as channels where antigens 
(including microbes) can reach the Peyer´s patches (small intestinal lymph nodes) and the 
lymphoid follicles (colonic lymph nodes), where they meet APCs such as dendritic cells and 
macrophages130. DCs express all types of TLR and NOD, enabling them to distinguish between 
commensals and pathogens and to either activate or silence T cell responses, which balances the 
immune response131. In healthy persons, T cell unresponsiveness is induced by the DCs that 
sample antigen and thus display an immature phenotype that stimulates naïve T cells to 
differentiation into regulatory CD4+T cells rather than effector Th1 or Th2 cells. When DCs 
sense pathogens, they mature, become activated and induce immunity132. This process 
represents an important aspect of how the immune homoeostasis of the healthy GI tracts is 
achieved. 
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1.9.5 Cytokines 
Cytokines refers to a broad category of small signaling proteins, approximately 5-20 kDa, that 
participate in the immune responses as immune-modulating agents, and are produced by 
macrophages, monocytes, T-cells, B-cells, DCs, NK-cells, bone marrow stromal cells, epithelial 
cells and fibroblasts. They take part in cell activation, growth, and differentiation, thereby the 
cytokines play an important role in the inflammatory process and immunity133, 134. The first 
cytokine was identified 1957 (interferon type I), and now decades later a broad spectra of 
cytokines like interferons (IFN), interleukins (IL), chemokines, mesenchymal growth factors 
(MGF), the tumor necrosis factor family (TNF) and adipokines are described135. Cytokines 
exert their function thorough autocrine signaling, paracrine signaling (from one cell to a nearby 
cell) and by endocrine signaling (via the circulation to a distant cell) and bind to a specific 
receptor. Thus, cytokines are able to mediate a variety of functions (pleiotropic) like recruitment 
of leukocytes and complex intracellular signaling involved in the inflammatory response136. The 
nomenclature is traditionally built from their function, divided into pro-inflammatory, 
regulatory and anti-inflammatory. Nevertheless, new reports suggest that at least the regulatory 
cytokines may have variable functions and are able to promote as well as hamper inflammation, 
depending on the immunological condition and timing137-139. An overview over the complex 
cytokine landscape in table 5. 
1.9.6 Chemokines and chemokine receptors 
Chemokines (chemotactic cytokines) are a subgroup of cytokines (8-12 kDa), produced by 
different cells in order to recruit leukocytes to the sites of inflammation (chemotaxis). The 
chemokines are divided into four families, CXC, C–C, C and CX3C, depending on where the 
N-terminal cysteine residues. Chemokine signals are transduced through binding to members of 
the seven-transmembrane G protein–coupled receptor (GPCR), and chemotaxis is induced when 
chemokines binds to the target cell with varying affinity to either one or several of their 
connected chemokine receptors (CCRs)136. To date, 23 CCRs that may exert chemotaxis have 
been identified, together with some 50 chemokine ligands140. The CCR system is complex and 
promiscuous; a single receptor has multiple chemokine ligands whereas a single chemokine 
binds to several receptors. Besides the chemotactic function, chemokines induce angiogenesis 
and additionally seem to be involved in T-helper cell differentiation either directly or indirectly 
by cytokine secretion or by alter the APC trafficking141. 
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Table 5. Cytokines, the main source, the target cells and the function of the cytokine.  
CYTOKINE MAIN SOURCE TARGET CELL FUNCTION 
 IL-1α, IL-1β, IL-
1ra, IL-18, IL-33, 
IL-36α, IL-36β, IL-
36γ, IL-36Ra, IL-37  
Mϴ, B-cells, DC B-cells, NK, T-cells Pyrogenic,pro-infl, proliferation, differentiation, 
BM cell profileration 
IL-2, IL-21  T-cells activated T -and B-cells, NK  Proliferation and activation 
IL-3 T-cells, NK stem cells Hematopoetic precursor, proliferation and 
differentiation 
IL-4 Th cells B-cells, T-cells, Mϴ Proliferation of B-cells andTcyt, enhances MHC 
class.II expression, stimulates IgG and IgE 
production 
IL-5 Th Eosinophils, B-cells Proliferation and maturation, stimulates IgA and 
IgM production 
IL-6, IL-11, IL-31, 
CNTF, CT-1, LIF, 
OPN, OSM 
Th, Mϴ, fibroblasts Activated B-cells, plasma 
cells 
Differentiatin into plasma cells, IgG production 
IL-7 BM stromal cells, epithelial cells Stem cells B- and T cell growth factor 
IL-8 Mϴ Neutrophils Chemotaxis, pro-inflammatory 
IL-9 T-cell T-cell Growth and proliferation 
IL-10, IL-19, IL-20, 
IL-22, IL-24, IL-26, 
IL-28, IL-29 
T-cell B-cells, Mϴ Inhibits cytokine production and mononuclear cell 
function, anti-inflammatory 
IL-12, IL-23, IL-27, 
IL-35 
T-cells NK-cells Activates NK-cells 
TNF-α Mϴ,monocytes Mϴ, tumor cells Phagocyte cell activation, endotoxic shock, tumor 
cytotoxicity, cachexia 
TNF-β T-cells Phagocytes, tumor cells Chemotactic, phagocytosis, oncostatic, induces 
other cytokines 
IFN-α Leukocytes Various Anti-viral 
IFN-β Fibroblasts Various Anti-viral, anti-proliferative 
IFN-γ T-cells Various Anti-viral, Mϴ activation, increases funtion of 
neutrofiles and monocytes  
G-CSF Fibroblasts, endothelium Stemcells in BM Granulocyte production 
GM-CSF T-cells, Mϴ, fibroblasts Stemcells Granulocyte, monocyte, eosinophil production 
M-CSF Fibroblasts, endothelium Stemcells monocyte production and activation 
ERYTROPOETIN Endothelium Stemcells Red blood cell production 
TGF-β T-cells, B-cells Activated T-cells and B-cells Inhibit T and B cell proliferation, inhibit 
hematopoiesis, promote wound healing 
Mϴ=macrophage, Th= T helper cell, NK= natural killer cell, DC= dendritic cell, BM= bone marrow 
 
 THE INTESTINAL IMMUNE SYSTEM IN IBD 
In patients with IBD, several immunological dysfunctions seem to prevail, involving both the 
innate and adaptive immune system. They appear to have reduced epithelial resistance and 
increased permeability in the mucosa with a subsequent leaky epithelial barrier37. T-cells 
mediated disruption of the tight junction and dysfunction of the enteric neuron are the supposed 
mechanism for this permeability142. Figure 2. Increasing evidence has shown that a disturbed 
innate immunity takes part in the pathogenesis of both CD and UC. Paneth cell defects in ileal 
CD leads to depressed expression of α-defensin while the expression of β-defensin is depressed 
in colonic CD143. 
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NOD2 is an intracellular PRR encoded by the NOD2 gene (chromosome 16). It recognizes 
peptidoglycans in the cell wall of bacteria and stimulates immune responses. Reduced NOD2 
function may be followed by the inhibition of TLR stimulation, leading to extremeTh-1 
response through different inflammatory pathways144. Patients with NOD 2 and Atg16L1 
mutations also seem to have impaired autophagy function, which is one of the immune 
dysfunctions seen in IBD. Bactericidal effects and presentations of antigens start the autophagy 
process in the cell and thus the lack of autophagy leads to excessive amounts of activated 
immune cells145. This event is due to a failure of central (thymic) and peripheral tolerance146. 
The epithelial cells in a healthy person express TLR3 and TLR5 (TLR 2 and TLR4 are difficult 
to detect). In patients with CD, but not in UC patients, TLR3 is significantly down regulated, 
whereas in both CD and UC patients TLR4 is strongly upregulated147. 
It has also been shown that the function of DCs is faulty in patients with IBD, both in the 
recognition and processing of the antigen. They incorrectly get triggered by the commensals 
and induce a Th1 (and possibly Th17) pro-inflammatory immune response normally restricted 
to pathogens120. Patients with IBD apparently have more activated DCs in the inflamed mucosa 
and a lack of tolerogenic DCs in the circulation that correlates with the extent of 
inflammation120. 
Individuals with IBD have disturbed apoptosis (programmed cell death), a condition leading to 
the persistence of hyper-reactive T cells. This event is due to a failure of central (thymic) and 
peripheral tolerance146. Overall, in active IBD the balance between effector T cells and 
regulatory T cells is disturbed. The effector Th1 and Th2 T cells predominate over regulatory T 
cells because of naïve T cells (T0), preferably differentiating into Th1 (in CD) 148. CD is 
considered driven by a Th1 immune response, whereas UC is known as a Th2-mediated 
disease149.  The activated effector T cells produce pro-inflammatory cytokines that stimulate 
macrophages to secrete large amounts of TNF-α, IL-1 and IL-6, thus enhancing the 
inflammation. The tissue damage is additionally exerted by IL-12-activated NK cells who secret 
pro-inflammatory cytokines and exercise a direct cytotoxic effect on their target cells. In 
addition, a large number of leukocytes enter from the intestinal microcirculation, releasing 
chemokines that attract more activated leukocytes. The vicious circle of both dysfunctional and 
upregulated innate and adaptive immune responses is thus perpetuated.120 
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Figure 2. The epithelial barrier and response to invading pathogens. Ref Metha et al24.
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2 AIMS AND OBJECTIVES 
General aim 
The overall aim of this thesis was twofold: (1) to study the clinical effect of Infliximab in 
children on maintenance treatment, and of granulocyte and monocyte apheresis and exclusive 
enteral nutrition in children with new onset IBD and (2) to examine the immunological profile 
in blood at onset and in intestinal mucosa in children at onset and post-treatment. 
Specific objectives 
 To study trough s-IFX and ATI to identify any correlation with inflammatory activity 
indicies and clinical response in 45 children on maintenance IFX treatment. 
 To investigate the clinical effect of GMA and mesalazine as induction of remission in 
children with new onset IBD colitis. 
 To examine the clinical effect of EEN in children with new onset CD. 
 To study the mucosal cytokine profile in children with IBD at onset and after induction 
of remission with GMA and EEN. 
 To look into the chemokine receptor pattern on circulating leukocytes in children with 
CD, UC and healthy controls to determine a prognostic marker in blood to distinguish 
UC from CD.
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3 CHILDREN AND METHODS 
An overview of the study design, methods and participants are presented in Table 5. 
Paper Design Study population 
at inclusion 
Number of 
participants 
Aim Method Statistical method 
I Cohort Children with IBD 
on maintenance 
IFX treatment 
45 To study s-IFX trough levels, ATI 
and associations with clinical 
activity. 
In-house developed 
ELISA, 
PUCAI/PCDAI, blood 
chemistry, 
f-calprotectin 
Pearson with 
cluster-robust 
standard error. 
Student T-test. 
II Cohort 
(pilot) 
Children with new 
onset IBD colitis 
13 To study the clinical effect of 
GMA and mesalazine as 
induction of remission 
PUCAI, Geboes score, 
endoscopic Mayo, 
 blood chemistry, 
f-calprotectin 
Paired sample t-
test, McNemar test 
III Cohort 
(pilot) 
Children with new 
onset UC, CD and 
non-IBD controls 
45 To distinguish CD from UC by 
expression of chemokine 
receptor pattern on blood 
leukocytes 
Flow cytometry, 
PUCAI/PCDAI,  
blood chemistry, 
F-calprotectin 
Univariate logistic 
regression, 
multivariate logistic 
regression 
IV Cohort Children with new 
onset IBD and 
non-IBD controls 
19 To study the clinical outcome of 
EEN and changes in the colonic 
mucosal cytokine profiles 
PCDAI, Geboes score, 
SES-CD, blood chemistry, 
f-calprotectin.  
Real time PCR 
Paired sample t-
tests, Wilcoxon 
paired t-test, 
Mann-Whitney U 
test. 
V Cohort Children with new 
onset IBD colitis 
and non-IBD 
controls 
13 
(7 IBD patients 
from study II) 
To study changes in the colonic 
mucosal cytokine profiles at 
onset and after GMA 
PUCAI, Geboes score 
endoscopic Mayo,  
 blood chemistry, 
f-calprotectin.  
Real time PCR 
Paired sample t-
tests, Wilcoxon 
paired t-test, Mann-
Whitney U test. 
Table 5. Overview of study design, method and study population. 
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All patients in paper I (the IFX study) (n=45, age 7–18 years, CD: n=32, UC: n=13) were 
enrolled between September 2013 and May 2015. The children were patients at the 
Gastroenterology Department at Sachs’ Children and Youth Hospital, Stockholm, Sweden, 
Astrid Lindgren Children’s Hospital, Solna and Huddinge, Sweden and at Västmanland 
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of other biological treatment. 
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The patients in paper II (the GMA study) (n=13) were previously healthy children from 12 to 
18 years of age. They were enrolled between December 2012 and April 2016 as a single-center 
study at Sachs’ Children and Youth Hospital. Inclusion criteria were previously healthy children 
with newly onset IBD ≥ 12 years of age and a body weight of a minimum of 30 kg. Exclusion 
criteria was UC with limited inflammatory extension, any use of immunosuppressant drug 
within six month of the study and a history of anxiety when exposed to intravenous cannulation. 
They were primarily diagnosed with UC according to the ECCO/ESPGHAN criteria for 
diagnosis of IBD44. However, after histopathological review, in two patients the diagnosis was 
changed to colonic CD. One patient left the study after five GMA sessions because of non-
response. Twelve (92%) patients completed the study according to the study protocol. 
In paper III (the chemokine receptor study), 16 UC patients, 12 CD patients and 17 healthy 
controls were recruited between December 2012 and June 2016. The IBD patients also 
participated in the GMA study (paper II) and EEN study (paper IV). The patients were 
diagnosed according to the ECCO/ESPGHAN criteria for diagnosis of IBD44 and an additional 
histopathological scoring implemented in the framework of the studies. Additionally, 10 
patients’ blood were used in this study from four UC patients who initially were included but 
left the studies, and in six children six without inflammation immediately after the diagnostic 
work-up. Eleven children, who were admitted for hand surgery or MRI scan under general 
anesthesia, served as healthy controls together with the six non-IBD patients described above. 
In paper IV (the EEN study), 19 patients were enrolled between August 2013 and September 
2016. Of these, 13 were initially diagnosed with CD according to the ECCO/ESPGHAN 
guildelines44. An additional six patients were recruited: one with a juvenile polyp and five 
without intestinal inflammation, referred to as the non-IBD controls (the same non-IBD controls 
as in paper III and V). Inclusion criteria were previously healthy children with new CD. 
Exclusion criteria were any use of immunosuppressant drug within six month of the study. One 
CD patient left the study after the diagnostic endoscopy. After completion of induction of 
remission with EEN and histopathological review, two patients had their diagnosis changed to 
UC.  
In paper V, the study population comprised seven patients from the GMA study (paper II, five 
patients with UC and two with CD colitis) and six non-IBD controls (the same non-IBD 
controls as in paper IV). 
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 STUDY DESCRIPTION 
3.2.1 Paper I 
Forty-five children contributed with one to four blood samples each (in total 93 samples). 
Serum samples of 2 mL were obtained before scheduled IFX infusion and were analyzed for s-
IFX (trough level) and antibodies towards IFX (ATI) using an in-house-developed ELISA. ATI 
could only be analyzed in samples with undetectable trough levels of IFX (<0.2 µg/mL). At 
least one sample was obtained in the framework of the study. Additional trough s-IFX already 
taken at the discretion of the treating physician outside this study was included in the analysis. 
Dose changes of IFX were not planned in the study. CRP, ESR and albumin were registered at 
every infusion. FCP was collected in 34/45 (76%) patients. PUCAI and PCDAI were calculated 
at the time of IFX infusion, except for approximately 20%, which were calculated 
retrospectively based on charts. CD patients were considered in remission when their PCDAI 
was <1045, CRP <5150 and ESR <10151; UC patients were considered in remission if the PUCAI 
was <1047, CRP <5 152 <and ESR <10. 
3.2.2 Paper II 
Twelve children with newly onset IBD colitis completed 10 GMA sessions with an additional 
low to moderate dose of mesalazine. Any use of additional treatments was recorded. Three 
months after complete GMA treatment, a control colonoscopy (CC) was performed. The time 
interval was chosen because of the suggested time for the development of a steady state 
leukocyte transmigration between blood and mucosa153. Blood count, ESR, CRP, albumin, F-
calprotectin, endoscopic Mayo scoring, Paris classification, PUCAI and Geboes histological 
scoring were measured and compared at disease onset and at CC. 
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Figure 3. Flow chart of the participants’ way throughout study II, III, IV and V. (The results of 
the one-year follow-up is not included in the studies presented in this theses) 
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3.2.3 Paper III 
This pilot study aimed at finding a prognostic marker in blood to distinguish UC from CD. 
Peripheral blood samples from children with new onset UC and CD (diagnosed according to the 
ECCO/ESPGHAN criteria) and from 17 children without IBD (or any other inflammatory 
condition who served as healthy controls) were analyzed with flow cytometry (LSR Fortessa) 
that allowed the detection of 20 chemokine receptors on lymphocytes (CD3+), B cells (CD19+), 
monocytes (CD14+) and granulocytes (CD16+). Expression levels for each CCR on the 
respective leukocyte population were calculated. A diagnostic algorithm based on these markers 
distinguished UC from CD in >92% of the studied cases. The disease characteristics were 
classified, and laboratory values as well as histopathological characteristics were described at 
onset. 
3.2.4 Paper IV 
Twelve children who were initially diagnosed with CD were treated with a polymeric EEN for 6 
weeks. Short time after completion of EEN, a CC was performed. Weight, height, albumin, 
blood count, ESR, CRP, F-calprotectin, SES-CD, Paris classification, PCDAI and Geboes 
histological scoring (with additional characteristics for CD) were measured at diagnosis and at 
CC. The colonic mucosal cytokine pattern (CMCP), measured by real time polymerase chain 
reaction (PCR), was investigated in six CD patients at diagnosis and at CC; in the remaining 
seven patients, the CMCP was analyzed either at diagnosis or at CC; in the six non-IBD 
controls, the CMCP was analyzed at the initial colonoscopy. The CMCP was compared in the 
six EEN-treated patients between diagnosis and at CC. In addition, CMCP comparisons were 
made between the IBD patients and the non-IBD controls. 
3.2.5 Paper V 
In seven of the GMA treated patients with IBD colitis that participated in paper II, the CMCP 
measured by real time PCR (see method below), was evaluated and compared at diagnosis and 
at CC. Additionally, the CMCP was investigated in six non-IBD controls at onset and compared 
with the children with IBD. Clinical outcome (measured with ESR, CRP, albumin, F-
calprotectin, Mayo sum and PUCAI) was compared at onset and at CC. Patient demography and 
disease extension (Paris scoring) were described at onset in all patients. 
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 GRANULOCYTE AND MONOCYTE APHERESIS WITH ADACOLUMN® 
In paper II and V, we used the Adacolumn® Apheresis system comprising of Adacolumn® 
(ADA) (column filled with cellulose acetate beads as the adsorptive carriers), Adamonitor 
(blood pump) and the Adacircuit (tubing). The blood is drawn into the column from a vein of 
one arm via a simple venipuncture, is pumped through the ADA and then returned to the patient 
via a vein of the contralateral arm. The session was performed during 60 minutes at a flow rate 
of 30 ml/minute with a single intravenous dose of intravenous heparin (5000 E) to prevent 
clotting of the venous catheter. The participants were given EMLA® cream (a local anesthetic, 
lidocaine 2.5% and prilocaine 2.5%) at least 1 hour before venipuncture. Figure 4 schematically 
depicts how the ADA treatment is performed. 
Figure 4. The ADA treatment (from Otsuka® Pharmaceutical homepage) 
 
 POLYMERASE CHAIN REACTION (PCR) 
In paper IV and V, we investigated the cytokines CSF-2, IFN-γ, TNF-α, IL-1β, IL-4, IL-5, IL-6, 
IL-10, IL-12B, IL-13, IL-22, IL-23α, IL-36γ, TGF-β1 and one control gene (ABL CT). The 
amount of mRNA in the 14 pro-inflammatory mediators was compared with the signal from the 
ABL gene and the result was presented as the ratio cytokine/ABL. Biopsies for the CMCP were 
put into RNA and kept at +6 ºC for 24 hours and then frozen (-20°C) until analysis. Total RNA 
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was isolated using the Fibrous tissue kit (Qiagen, Hilden, Germany). The defrosted and minced 
biopsies were homogenized and 70% ethanol was added. The homogenates were loaded to spin 
columns, centrifuged and the columns were washed with RW1 buffer and then treated by 
DNase I and washed again with RW1 buffer. The remainder was handled according to the 
manufacturer’s protocol. cDNA was obtained by reverse transcription. Quantitative real-time 
PCR (qPCR) was performed using the 7500 Fast Real Time PCR System (Applied Biosystems, 
Foster City, CA, USA) for quantification. Probes were obtained from Applied Biosystems 
(TaqMan® MGB probes, FAM™ dye-labeled) according to manufacturer’s protocol. Fold 
increases of mRNA transcripts were calculated as follows: ΔCt = Ct (gene of interest) − Ct 
(ABL1), ΔΔCt = ΔCt sample − average ΔCt control group and fold difference = 2−ΔΔCt. For 
more detailed information, see paper IV and V. 
 
 FLOW CYTOMETRY (FACS) 
In paper III, we used fluorescence activated cell sorter scan (FACS) analysis of chemokine 
receptor expression on four leukocytes T-lymphocytes (CD3+), B cells (CD19+), monocytes 
(CD14+) and granulocytes (CD16+). The leukocytes were isolated from heparinized whole blood 
samples by incubation in a hypotonic buffer, followed by a blockade of unspecific Fc-receptor 
interactions by incubation in phosphate-buffered saline supplemented with 10% human serum. 
This procedure was followed by surface staining using combinations of fluorochrome-labelled 
antibodies. Isotype and fluorochrome-matched control antibodies were used to define marker 
positivity. It is a well-established fact that the accuracy and robustness of the flow cytometry 
method constitute a limitation with regards to separating negative populations from those that are 
dimly positive. This can be due to experimental assumptions in the antibody conjugate staining 
protocols, as well as day-to-day variations in the optical performance of the flow cytometer. 
Therefore, we excluded those variables that had a measured isotype-control normalized MFI of 
<300 in both disease groups from the analysis (Table 1) and 52 variables were excluded from 
further analysis. FACS analyses were performed on an LSR Fortessa cytometer (BD 
Biosciences). The raw data files from FACS analyses were imported into FlowJo software 
(Treestar Inc.), which was used for all data generation. For more detailed information, see paper 
III. 
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 STATISTICAL ANALYSES 
Paper I: The correlation between s-IFX (dependent variable) and ESR, CRP, albumin and 
clinical scoring (independent variables) were assessed with linear regression using the standard 
error to test univariate associations. Other intergroup comparisons were performed with two-
tailed t-tests. A simple linear regression was conducted to correlate changes in dose to changes 
in trough IFX. In all statistical analyses, one outlier (IFX trough level 40 µg/mL) was excluded. 
Paper II: The Shapiro Wilks test was used for normality testing in all parameters and 
comparisons between ESR, CRP, albumin, Hb, F-calprotectin and Mayo endoscopic score 
before and after treatment were conducted with paired sample t-tests. The McNemar test was 
used to compare correlations of PUCAI before and after ADA treatment. 
Paper III: First, statistical exclusion criteria were established to reduce the number of analytical 
variables and remove chemokine receptors that did not have predictive value. Logistic 
regression was then used and 28 univariate logistic regression analyses were performed. These 
28 univariate logistic regression analyses revealed four chemokine receptors CXCR4 (CD3+), 
CXCR1 (CD16+), CCR9 (CD14+), CCR4 (CD14+) that had a corresponding p-value of ˂0.1. 
Those four chemokines were then put into a multiple logistic regression model. The likelihood 
ratio test revealed that the model had a p-value of p=0.0033. The model managed to separate the 
data correctly in 92.31% of the cases in the dataset. See paper III for more detailed information 
of the logistic regression models. 
 
Paper IV and V: The Shapiro-Wilks test was performed to test normal distribution in clinical 
chemistry values, weight, height, SES-CD (paper IV), Mayo endoscopic score (paper V) and 
clinical scoring. Comparisons before and after treatment were performed for all parameters with 
paired sample t-tests (if parametric) or Wilcoxon paired t-tests (if non-parametric). Cytokine 
profiles before and after treatment were performed with the Wilcoxon paired t-tests and Mann-
Whitney U test to compare cytokine profiles between groups. 
 
All statistical analyses were performed with IBM SPSS Statistics 23 Data Editor® software (all 
papers) and Stata 13.1 (paper I). Statistical significance was set at p˂0.05.  
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 ETHICAL APPROVAL 
In all studies, patients aged ≥15 years and the parents/caregivers to children < 15 years gave 
written informed consent to participate in the studies before any study-related procedure was 
initiated in accordance with the Helsinki II Declaration. All studies were approved by the 
Regional Ethics Committee in Stockholm, Sweden (No. 2011/1927-31/2, No. 2010/1252-31/1 
and No. 2012/378-31/3).  
 
4 RESULTS 
 
 S-IFX TROUGH LEVELS, ATI AND CORRELATION TO INFLAMMATORY 
MARKERS 
In Paper I, the children had received a mean number of 13 IFX infusions (range 4-48, mean 
interval 44.8 days (SD ± 11.2, range 3.44-10.5)) and a mean IFX dose of 6.4 mg/kg (SD ±1.7) 
mg/kg was measured. The patients showed clinical remission (PCDAI <10 or PUCAI <10) at 
44 of 93 visits (47%). When clinical remission was defined with a stricter definition, including 
clinical scoring <10, CRP <5 and ESR <10, the patients showed remission only at 26 of 93 
visits (28%).  
The mean s-IFX trough level was 5.2 µg/mL (median 4.5 µg/mL, range <0.2-21), showing a 
significantly higher s-IFX level during remission (mean 7.2 µg/mL) compared with during 
active disease (mean 4.5 µg/mL) (Figure 5).  
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Figure 5. The mean trough s-IFX level was significantly higher in the samples taken during remission (7.2 µg/mL) as compared 
with s-IFX in active disease (4.5 µg/mL) (p<0.05). 
 
ATI was found in 12 samples from eight children. All of them were in active disease at every 
sample occasion. Furthermore, in six additional children, s-IFX was detectable but <1.0 µg/mL 
and all but one of these were in active disease.  
When the patients in active disease and remissions were compared, no significant differences 
were evident in dose interval (43 days for patients in active disease vs. 42.7 days in remission, 
p=0.88) or in mean IFX dose (6.4 mg/kg for children in active disease vs. 6.5 mg/kg in 
remission, p=0.76). Additionally, no clear correlation was seen between IFX trough levels and 
intra-individual variations in dosing (mg/kg/infusion intervals in days). 
IFX trough levels and disease activity were associated, showing negative correlations with 
clinical indices (p=0.0259), CRP (p=0.0084), ESR (p=0.0035) and a positive correlation with 
albumin (p=0.00059). 
 
 GMA AND MESALAZINE AS INDUCTION OF REMISSION IN CHILDREN 
WITH NEWLY ONSET IBD 
In paper II, 12 of the 13 participants completed 12 GMA sessions over a median period of 6.25 
weeks (range 4.5-8) with an additional dose of mesalazine (39-65 mg/kg). One patient 
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prematurely retired from the study owing to non-response. At onset, extensive or pancolitis was 
found in all patients. No serious adverse events occurred during the treatment period. 
Throughout the treatment, none of the patients showed a worsening of symptoms. In the time 
between complete ADA treatment and CC, three patients had a flare (after 4, 15 and 62 days) 
and were treated with prednisolone (1.5 mg/kg, 0.5 mg/kg and 0.3 mg/kg, respectively) for 4-6 
weeks. One of the flaring patients also suffered from concurrent pancreatitis. 
Disease activity: A cross-table analysis (McNemar test) with two subgroups at diagnosis 
revealed that patients with a PUCAI <35 (none to mild disease) and PUCAI ≥35 (moderate to 
severe disease) demonstrated a significant decrease in PUCAI at the time of CC (p=0.004). 
(Table 6). Of the three prednisolone treated patients, one was in clinical remission and two were 
in active disease. (Table 6). 
Table 6. Disease activity: PUCAI scoring at the time of diagnosis, the 10th ADA and the CC.  
 
PUCAI at diagnosis 
N=13 
PUCAI at 10th ADA 
N=12 
PUCAI at control colonoscopy 
N=12 
Remission <10 p 0 6 8 
Mild 10-34 p 1 4 2 
Moderate 35-64 p 10 2 2 
Severe ≥65- 85 2 0 0 
 
Laboratory values: Laboratory values were measured at onset and at CC. Significant decreases 
were seen in Hb (p=0.002), albumin (p=0.019) and F-calprotectin (p=0.005); a non-significant 
decrease was observed in ESR (p=0.058), whereas no decrease was noted in CRP (p=0.133). 
Mucosal Healing: After the 10th ADA session, CC was performed in all children at a median of 
93 (range 62-122) days. The mean Mayo score based on four segments was 1.75 at onset and 
0.75 at CC (p=0.006). Of the three patients treated with prednisolone, one had mucosal healing 
and the other two showed no mucosal healing. Complete mucosal healing (according to the 
Geboes score) was seen in two patients and improvement in an additional five patients. 
One-year follow-up: When more than one year had passed (34-48 month) after inclusion for 10 
of 12 patients, 5 still used mesalazine but had never required any supplemental IBD treatment. 
One more child received CS due to a flare several months after CC in addition to the three 
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children treated with CS due to flares between GMA and CC. The CS treated children and 
additionally one patient (not treated with CS) received azathioprine as maintenance treatment.  
 CHEMOKINE RECEPTOR EXPRESSION ON BLOOD LEUKOCYTES 
Paper III: By profiling the chemokine receptors on circulating T-lymphocytes (CD3+), B cells 
(CD19+), monocytes (CD14+) and granulocytes (CD16+), the expression pattern of CCR9, 
CCR4, CXCR1 and CXCR4 enabled a clinical distinction between UC and CD in >92% of the 
patients. 
 CLINICAL OUTCOME OF EEN 
In Paper IV, 12 children, 10 with CD and 2 with UC, completed 6 weeks with an EEN 
(polymeric diet) without the need of a feeding tube. No adverse effects were noted, except for 
mild stomach pain in two patients that could be ignored. 
Disease activity: A significant decrease was found in PCDAI at CC (p=0.02): median PCDAI at 
inclusion was 26.5 and only 5 after EEN induction treatment. Ten of 12 patients (83%) showed 
clinical remission (PCDAI <10) after EEN induction treatment. 
Laboratory tests and anthropometric data: Significant decreases were found in ESR, CRP and F-
calprotectin and significant increases in albumin, Hb, height and weight (Table 7). 
 Table 7. Laboratory values, weight and height at inclusion and at control colonoscopy 
Value  At inclusion 
Median (IQR) range 
After EEN treatment 
Median (IQR) range 
P-value 
Weight (kg) 
 
37.9 (31.5-52.6) 27.5-59.7 40.5 (32.8-55.4) 29.8-59.1 0.003 
Height (cm) 152 (148.5-165.6) 139-172.5 152.8 (147.7-166.0) 139.5-172.5 0.027 
ESR (mm/h) 28 (17.3-27.5) 8-53 9 (8-11) 2-21 0.005 
CRP (mg/L) 14 (2-49.3) 1-86 2.5 (1-8.3) 1-20 0.016 
Albumin (g/L) 33 (25-36) 24-41 36.3 (33.5-40.5) 31-44 0.003 
Hemoglobin (g/L) 113 (101-119.5) 83-142 129 (121-135) 116-144 O.001 
F-calpro (mg/kg) 2640 (1191-3169) 580-6360 620 (198-1556) 5-2256 0.033 
 
Mucosal healing: The CC was performed at a median of 13 (range 1-45) days after completed 
EEN. In comparison with the diagnostic endoscopy, a significant decrease (p=0.008) was noted 
in SES-CD after complete EEN. The mucosal biopsies were histologically scored using the 
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Geboes score with an addition for CD characteristics. The Geboes score showed improvements 
in 10 patients, worsening in 1 and no inflammation in 1. 
 COLONIC MUCOSAL CYTOKINE PROFILES AND CLINCAL OUTCOME 
The colonic mucosal cytokine profiles (CMCP) were measured in biopsies of the EEN-treated 
patients (paper IV) and in the GMA-treated children (paper V). Due to circumstances beyond 
our control, the CMCP was not investigated in all the participants who participated in the 
studies included in this thesis. 
In six EEN-treated patients, paper IV, who completed 6 weeks of EEN, decreases as well as 
increases in the cytokine expressions were seen in individual patients. In most pro-inflammatory 
cytokines decreases were seen, and in the anti- and regulatory cytokines, both decreases and 
increases were observed.  
We also compared the CMCP in the available biopsies from inclusion (n=8) and in the available 
biopsies after EEN treatment (n=7). Non-significant decreases were seen in IL-1β (p=0.064) 
and IL-23α (p=0.064). When the CMCP in six non-IBD controls was compared with that of the 
eight IBD patients at inclusion, significantly higher values of IL-12β (p=0.007) and IL-23α 
(p=0.025) were observed in the IBD patients. 
In paper V, seven patients treated with GMA and mesalazine indicated significant decreases in 
CSF-2 (p=0.018), TNF-α (p=0.028), IL-23α (p=0.043), IL-1β (p=0.028), IL-36γ (p=0.018), IL-
10 (p=0.028) and TGFβ1 (p=0.043). For IL-4 (p=0.068), IL-5 (p=0.068) and IL-6 (p=0.075), a 
decreasing trend, though not statistically significant, was observed after induction treatment. No 
significant differences could be detected in IFN-γ (p=0.176), IL-12β (p=0.499), IL-22 (p=0.398) 
and IL-13 (p=0.138). 
Looking at comparisons between IBD patients and non-IBD controls at disease onset, the 
CMCP showed significantly higher IL-12β (p=0.023) and IL-23α (p=0.046) in the children with 
IBD. A higher expression of IL-22 (p=0.088) and IL-36γ (p=0.062) was found in the IBD 
patients but without reaching statistical significance. 
In paper V, clinical outcome was also investigated showing a median PUCAI of 50 (IQR 40-70, 
range 30-80) at inclusion; at CC, there was a significant improvement in PUCAI (median 0, 
IQR 0-15, range 0-25) (p=0.001). The endoscopic Mayo scoring showed additionally significant 
improvement (p=0.013) between inclusion (median 7, IQR 6-9, range 6-12) and CC (median 3, 
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IQR 0-3, range 0-6) as well as ESR (29-9.7, p=0.048), F-calprotectin (3825-872, p=0.032) and a 
significant raise of albumin (35-40.6, p=0.015). 
 
5 GENERAL DISCUSSION 
The general aim of the theses was to investigate the clinical outcome of three CS free treatments 
and the subsequent immunological effects exerted in blood and colonic mucosa. 
IBD in children consists of a broad spectrum of phenotypes, and does not only refer to the two 
entities (CD and UC), but also how the disease behaves in the individual patient. Given the 
difficulties in correctly diagnosing patients, the possibilities to optimize the treatment might be 
limited. Indeed, prognostic markers, a growing arsenal of treatments and tools to even better 
evaluate treatment outcome are challenges for the future. Another problem in pediatric IBD care 
is the wide use of CSs. As a pediatrician, it is highly unsatisfactory to give the child a treatment 
you know most certainly will cause side effects and probably not compel the child into mucosal 
healing. 
 IFX TROUGH LEVELS AND ANTIBODIES TO IFX 
In paper I, our aim was to correlate s-trough levels and ATI to clinical activity and response in 
45 children (CD: n=32 and UC: n=13) on maintenance IFX treatment. Our findings revealed 
surprisingly low numbers of patients in remission. When clinical scoring was measured 
(PUCAI or PCDAI <10), the children were in clinical remission in 44 of 93 visits (47%). 
However, when a stricter definition of remission was applied (CRP <5, ESR <10 and clinical 
scoring <10), clinical remission was observed in only 26 of 93 visits (28%). In line with other 
reports, we found statistically significant correlations between s-IFX and clinical indices, as 
well as with CRP, ESR, and albumin levels, with the exception for F-calprotectin99, 100, 154. A 
comparatively high mean dose of IFX was found (6.4 ±1.7 mg/kg) and a mean s-IFX trough 
level of 5.2 µg/mL (range < 0.2-21), with a much higher s-IFX during remission (mean 7.2 
µg/mL) compared with the children in active disease (mean 4.5 µg/mL) (p<0.05). Two previous 
reports on s-IFX trough levels in children described a median s-IFX of 3.5 µg/mL, and yet 
another reported 1.9 µg/mL at week 30 and 2.6 µg/mL at week 46 when receiving 5 mg/kg92, 154, 
155. The children in these studies were subjected to active therapeutic drug monitoring (TDM) 
which differs from our study in which the patients reflect an everyday clinical setting. TDM 
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reports on s-IFX trough levels in children described a median s-IFX of 3.5 µg/mL, and yet 
another reported 1.9 µg/mL at week 30 and 2.6 µg/mL at week 46 when receiving 5 mg/kg92, 154, 
155. The children in these studies were subjected to active therapeutic drug monitoring (TDM) 
which differs from our study in which the patients reflect an everyday clinical setting. TDM 
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refers to the clinical practice of measuring specific drugs at designated intervals to maintain a 
constant blood concentration of the drug in order to optimize individual dosage regimens156. 
Loss of response to anti-TNF is common. Several studies have shown that only 25-41% of adult 
patients have a sustained response to anti-TNF treatment after 1 year157, 158, showing better 
results in children. De Bie et al. showed that the probability of losing response to IFX in a 
pediatric population was 13%, 40% and 50% after 1, 3 and 5 years, respectively. In another 
study, Vahabnezhad et al. found that in children with CD, 88% remained on IFX at 1 year, 80% 
at 2 years and 82% at 5 years159, 160. In our report, low s-IFX was associated with the formation 
of ATI, which was found in 12 samples from eight children, all in active disease. Loss of 
response was first described by Baert et al. and was demonstrated to be closely correlated to 
ATI161, 162. Most studies, including our study, have used a method which allows ATI to be 
measured only in the absence of IFX. Nevertheless, Vande Casteele et al. showed (their method 
allowed for the analysis of ATI in the presence of the drug) that the presence of ATI, even at 
therapeutic concentrations of IFX, increased the probability of active disease163. It is 
conceivable that the same condition prevails in the pediatric population. To monitor the patients 
thoroughly seems to be a very important factor in IFX treatment outcome. The current strategy 
is to treat the patients with an induction treatment at week 0, 2 and 6, of 5 mg/kg and a 
subsequent maintenance treatment of approximately 5 mg/kg, and wait with a dose-escalating 
until the patients prove to have active disease in combination with sub-therapeutic drug 
concentrations40, 101, 164. This approach probably allows for formation of ATI which may lead to 
decreasingly concentrations of the drug and finally results in loss of response. Many factors, 
except of ATI, have been described to influence the clearance of IFX; gender, disease 
phenotype, body size, albumin concentration and concomitant immunomodulators101. The 
pivotal SONIC study investigated the associations of IFX, immunomodulators and remission, 
and found that 96 of 169 (56.8%) adult patients who received IFX and concomitant 
immunomodulators were in corticosteroid-free clinical remission at week 26 compared with 75 
of 169 patients (44.4%) receiving IFX alone165. In children, Grossi et al repeated these results, 
and showed that IFX treated CD patients on concomitant immunomodulators for > 6 months 
after starting IFX, increased the chances to remain on IFX91. Interestingly, in our study, only 28 
of 93 samples (30%) were collected at the time of concomitant immunosuppression. Mean 
trough IFX was 6.5 µg/L (0.2–21) compared with 4.8 µg/L (0.2–14) in samples from patients on 
monotherapy (n = 65, 70%) without reaching a significant difference between the two groups. 
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In order to optimize the management of s-IFX trough levels, investigations of s-IFX during 
induction treatment have been studied. One pediatric study investigated the s-IFX in 77 patients 
in week 10 of induction, and yet in another study of 291 adult IBD patients, as early as after 2 
weeks of induction. These induction periods proved effective in predicting 1-year outcome 
(trough levels at week 10) and for short term and medium term clinical efficacy in UC patients 
(trough levels at week 2) but in CD, week 2 trough levels were only associated with short-term 
clinical outcomes166, 167. A new way of optimizing the anti-TNF dosing is described by 
Dubinsky et al. by using a prototype dashboard to compare forecasted dosing regimens with 
actual administered regimens and a standard of care regimen (5–10 mg/kg and an interval every 
6–8 weeks). Fifty children completed induction treatment and maintenance treatment (weeks 14 
– 54) and clinical and laboratory values, S-IFX and ATI were measured at week 14 and 54. 
They found that the dashboard recommended dose and/or interval changes in 48/50 patients and 
that standard of care dosing was recommended in 11/50 patients. The authors conclude that 
dashboards will be an important tool to individualize the IFX treatment for achieving a durable 
remission. 
Other mechanisms of loss of response are also important to recognize. Low albumin values are 
known to correlate to low s-IFX168. Brandse et al. elegantly showed IFX loss through the feces, 
and even more, that patients with low albumin concentrations had higher fecal IFX 
concentrations at day 1 and subsequently lower s-IFX at week 2. This finding probably reflects 
a general protein loss followed by an extensively ulcerated intestinal surface169.  
A limitation of our study is the small number of participants and the use of a retrospective 
design. The strength may be that our study reflects the reality of patients not being subject to 
active TDM. Therefore, conclusions about the role of active TDM-based IFX treatment were 
beyond the scope of this report. In summary, a very active and alert approach (which was not 
the case in our study cohort) with early and ongoing s-IFX trough levels for dose optimization, 
additionally thorough work-up with inflammatory parameters and clinical scoring, as well as an 
active decision if concomitant immunomodulators is suitable, seems to be a wise strategy to 
maintain response to IFX treatment.  
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 GMA FOR INDUCTION OF REMISSION AND CHANGES IN MUCOSAL 
CYTOKINE PROFILES 
In paper II (a pilot study), we flipped the traditional treatment algorithm by using the most 
often last treatment option: GMA, in combination with a low to moderate dose of mesalazine, as 
induction of remission treatment to newly onset IBD colitis patients. Twelve children, 10 with 
UC and 2 with CD colitis, completed 10 GMA sessions according to the study protocol. Our 
findings revealed an effective treatment with a significant decrease in PUCAI, F-calprotectin 
and ESR and a significant rise in Hb and albumin. Additionally, nine children achieved 
endoscopic significant remission (Mayo scoring) and two of these were in complete histologic 
remission (Geboes scoring). To the best of our knowledge, only one report on GMA as early 
induction therapy in the treatment of naïve children has been published. Tanaka et al. included 
24 children with newly onset UC who received 5-ASA or sulphasalazine treatment. Seventeen 
of the 24 children were non-responders and were then treated with 11 sessions of GMA 
followed by clinical evaluation and control endoscopy. GMA was associated with clinical 
remission and mucosal healing in 12 of the 17 GMA monotherapy-treated patients. In non-
responders to GMA monotherapy (five patients), an additional low dose of Prednisolone 
enhanced the efficacy of the GMA therapy. Furthermore, tapering of the Prednisolone dose 
soon after remission was not associated with UC relapse107. The authors discuss the importance 
of giving GMA early in the disease course. Previous studies (20 to 40 patients included) have 
shown that steroid naive (adult) patients with short duration of UC are the best responders to 
GMA treatment, especially compared with patients with deep colonic lesions and extensive loss 
of the mucosal tissue at UC lesion. Further, that the amount of used CS was significantly lower 
in CS treated patients who received additional GMA treatment 106, 110, 170-172.  
 Why were only one third of the patients in remission? Many patients were tested for s-IFX for 
the first time when they participated in this study. Are children without TDM without control? 
 Is this very expensive treatment not what we hoped for? Is it ethical to keep the patients on 
maintenance treatment without remission? And in that case how should the remission be 
evaluated? 
 Do doctors have too strong reliance on anti-TNF? If that is the case, is it because of the limited 
arsenal of treatments, or is it connected with the pharmaceutical industry and how anti-TNF 
has been presented? 
 Practical matters: If I had known, I would have talked to the statistician or some other skilled 
person about how to enter the data in the best way directly into the statistical program. That 
would have saved me from a lot of extra work.  
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In 2003, Tomomasa et al conducted the first pediatric study on 12 steroid refractory children in 
active UC who were treated with one GMA session for 5 to 10 weeks. Eight of these patients 
achieved significant clinical and endoscopic remission173. This study is followed by a handful of 
pediatric reports. Ruuska et al, for instance, showed significantly reduced steroid dosage in 37 
steroid-dependent children after five to nine GMA sessions174. In addition, some other, small 
studies (four to nine patients) have reported encouraging results175, 176.  
Based on the study protocol, the participating children in our study were diagnosed with UC 
according to the ECCO/ESPGHAN criteria44. After pathology review of the biopsies, two 
patients had a change in diagnosis to CD colitis. According to the largest genotype association 
study to date, in which the biological relations between CD and UC were studied, Cleynen et al. 
suggest that three distinct groups (ileal CD, colonic CD and UC) better explain the phenotypes 
in IBD. The authors further propose that this nomenclature should be used in a clinical context. 
Based on this recommendation, we did not exclude the CD patients from the study. In fact, it 
turned out that the CD patients were good responders to the induction of remission treatment28.  
In paper V, we investigated the (CMCPs) in 7 (five with UC and two with CD) of the 12 GMA 
patients who participated in paper II. The cytokine expression was investigated with real time 
PCR at onset and after treatment in the seven GMA patients as well as in six patients without 
intestinal inflammation (non-IBD controls). Fourteen cytokines (pro-inflammatory, anti-
inflammatory and regulatory) were measured. After induction treatment, significant decreases 
were noted in CSF-2, TNF-α, IL-23α, IL-1β, IL-36γ, IL-10 and TGFβ1 and non-significant 
decreases in IL-4, IL-5 and IL-6. We also found significant higher levels of IL-12β and IL-23α 
as well as non-significant higher values of IL-22 and IL-36γ between the IBD patients and the 
non-IBD controls at onset. ESR, F-calprotectin, PUCAI and the endoscopic Mayo score were 
found to significantly decrease after treatment compared with onset values; a significant rise in 
serum albumin was also observed. To our knowledge, this is the first report on CMCPs after 
GMA with mesalazine for induction of remission in pediatric patients. There are only a few 
reports in this area on adult patients. Yamamoto et al. studied the clinical and endoscopic 
outcome as well as cytokine profiles after GMA in 28 adult patients177. They found significant 
decreases in IL-1β, TNF- α and IL-6, which agrees with our results for children. Velikova et al. 
reported upregulated gene expression of several cytokines in 37 adult patients with active IBD 
and higher gene expression in the IBD patients compared with 12 non-IBD controls. They also 
correlated the cytokine gene expression of the IBD patients to different anti IBD treatments and 
found that Azathioprine ± 5-ASA or CSs were more beneficial than 5-ASA to restore immune 
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regulation. One limitation of paper II and IV is the small sample size, but a more serious 
limitation is that the results mirror the mesalazine treatment alone. We used GMA together with 
mesalazine for medico-ethical reasons to avoid the risk of giving the patient a non-effective 
treatment. Romano et al. studied the effect of high-dose mesalazine (80 mg/kg) remission 
treatment in 15 pediatric UC patients of whom 10 were newly diagnosed. Endoscopic remission 
at week 12 was found in 4 of the 15 children, which may support the notion that mesalazine 
alone would not have been sufficient as induction of remission in the present study. Indeed, the 
children in our study all suffered from extensive or pan-colitis and would probably have been 
treated with CSs in a standard care setting. Three children also received CSs between the 10th 
GMA session and CC because of flares, and two of these were still in active disease at CC 
despite the CS treatment. The investigation of the CMCPs in children after GMA and 
mesalazine is an unexplored research area with no available studies for comparison. A known 
mechanism of GMA is the removal of activated blood leucocytes, cells known to be important 
producers of pro-inflammatory cytokines178’133. Thus, we speculate that the clinical efficacy 
mirrors the decreased cytokine expression after GMA and mesalazine as induction of remission, 
and given the low level of side effects, this is a highly favorable treatment in children with IBD. 
Nonetheless, we recommend a larger controlled clinical trial comparing GMA and mesalazine 
against CS as an induction of remission in treatment naïve children with IBD colitis.  
 
 
 
 The GMA study was exciting to perform. The patients/parents were very content with the CS free 
treatment, and so was I. 
 
 I know that many colleagues do not have confidence in the GMA treatment. And of course, no big RCTs 
have been performed except from one that was made on adult patients in active disease who were on 
concomitant treatments, far from treatment naïve children. Is it an effective strategy to eliminate the 
cytokine producing cells before they reach the site of inflammation? If the answer of that question is yes, 
GMA is probably an effective treatment. 
 
 Besides no big RCTs, I believe that the expense of GMA makes it difficult to implement GMA in the 
healthcare. Is it ethical to NOT perform a head-to-head RCT on GMA vs CS? After all, this is a well-
tolerated non-steroid remission treatment.  
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 CHEMOKINE RECEPTORS ON BLOOD LEUKOCYTES AS A PROGNOSTIC 
MARKER FOR CD AND UC 
 
Paper III is a pilot study that aimed to find a prognostic marker for UC and CD in blood at 
disease onset. We set out to characterize cell surface chemokine receptor (CCR) expression on 
the leukocytes in blood from children in the GMA (paper II and V) and EEN study (paper IV) 
and in non-IBD controls. We identified four CCRs: CCR9, CCR4, CXCR1 and CXCR4, whose 
expression pattern enabled a clinical distinction between UC and CD in >92% of the cases in 
our study cohort. Presumably, this pilot study is the first to investigate whether CCRs can be 
used as a prognostic marker for pediatric UC and CD. There is an urgent need for more accurate 
and less invasive diagnostic methods. It can be difficult to diagnose children with newly onset 
IBD, where a mistaken diagnosis could lead to either an incorrect treatment or an inferior one 
followed by delayed remission. EEN is suggested as the first-line therapy to induce remission in 
children with CD, whereas in UC the first-line treatment is traditionally CSs40, 41. In a Swedish 
register-based cohort study the diagnosis for many patients changed during the follow-up 
period. According to unpublished data (Olén et al), about 3% of the children primarily 
diagnosed with CD had their diagnosis changed to UC, approximately 10% diagnosed with UC 
had their diagnosis changed to CD and almost 45% diagnosed as IBD-U had their diagnosis 
changed to either CD (36%) or UC (19%). The IBSEN study showed that in 9% of the cases the 
diagnosis changed between the entities179. Even more troubling is that a delayed diagnosis may 
be followed by a lag in pubertal growth spurt and impaired adult height180. Studies investigating 
non-invasive diagnostic markers in children with IBD are limited. One study showed that the 
presence of a specific volatile organic compound (VOC pattern) in the exhaled breath 
discriminated between IBD patients and controls181. Monasta et al. further explored this issue 
with a case-control study (pilot) using ion molecule reaction-mass spectrometry and studied 
whether the alveolar air of 67 children with IBD (33 UC and 34 CD) presents a specific VOC 
pattern when compared with controls (65 controls with GI complaint and 102 healthy 
controls)182. The authors found that pediatric IBD patients (and CD patients in particular) have 
different alveolar air VOC patterns compared with healthy children and gastroenterological 
controls. They also noted that CD and UC present different VOC patterns.  
A limitation of our study is the small sample size, followed by the important question 
concerning whether the results are applicable to the IBD population in general. The participants 
in our study were investigated according to the ECCO/ESPGHAN guidelines44, with a 
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subsequent histopathological scoring applied within the framework of the study. Thus, the 
patients had a clear diagnosis of CD or UC. Furthermore, no active selection of the patients was 
performed and thus the participating patients mirror those patients in a standard clinical setting. 
We suggest that it would be valuable to further explore the use of CCRs on blood leukocytes as 
a diagnostic biomarker for CD and UC in treatment-naïve children. 
 EEN FOR INDUCTION OF REMISSION AND CHANGES IN MUCOSAL 
CYTOKINE PROFILES  
EEN is the standard treatment for children with CD according to the European guidelines40, but 
the mode of action is not elucidated. In study IV, we aimed to investigate whether the effect of 
EEN as induction therapy was paralleled by changes in the CMCP. Eleven of 12 (92%) children 
completed 6 weeks of EEN, apart from one child who completed only 4 weeks. The children 
received a polymeric nutritional drink (Fortimel Energy®) that was taken orally by all patients. 
We found significant decreases in PCDAI, CRP, ESR, SES-CD and F-calprotectin and a 
significant increase in Hb, albumin, weight and height after induction of remission with EEN as 
a monotherapy. Ten of the 12 patients (83%) achieved clinical remission and histological 
scoring showed improvement in 10 patients, worsening in one and no inflammation in one. 
It is well-known that EEN is an equally effective remission treatment compared with the 
previously used first-line treatment (i.e. CSs), but EEN is superior in achieving mucosal 
healing79, 183, 184. Furthermore, one study showed nearly equal effectiveness between anti-TNF 
and EEN in clinical outcomes (PCDAI) and mucosal healing as estimated by fecal 
calprotectin185. Nevertheless, a new American review with the aim to assess the efficacy of EEN 
was initiated because CSs are still frequently used to induce remission in pediatric CD despite 
the potential adverse events in children. They found no difference in efficacy between EEN and 
CSs, and that a greater proportion achieved mucosal healing than the CS treated children, thus 
the same result as previous reports186. It has previously been shown that pediatric 
gastroenterologists in North America found their concern of patient adherence as the main 
disadvantage with EEN187. Svalos et al. investigated the opinion of the use of EEN and 
alternative novel, solid food-based diets (SFDs) in 29 children previously treated with 8 weeks 
of EEN (parental attitudes were also measured). They found that while patients with CD and 
their families would accept an EEN repeat, the majority preferred a SFD188. Unfortunately, we 
did not follow the patients with any questionnaire forms regarding quality of life. However, our 
overall impression is a good acceptance of the EEN treatment (except for one child who 
completed only 4 weeks) and thus our results are in concordance with Svalos et al. Except from 
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two patients who suffered from mild stomach pain during intake of the nutritional drinks, no 
adverse or side effects could be detected in our study population. We treated the patients with a 
polymeric nutritional drink because of its better taste that permits oral intake. No significant 
differences in efficacy have been reported (with endpoint mucosal healing) between elemental, 
semi-elemental and polymeric formulations76. In our study population, and especially in the 
case of the teenage patients, the offer of a feeding tube was out of the question. Consequently, 
none of the children used a feeding tube and 11 successfully completed 6 weeks of EEN. Before 
start of the induction treatment, the doctor had a lengthy conversation with the children and 
their parents about treatment options and the advantage EEN therapy in terms of its high 
quality. A dietician had close contact with the patients and their parents throughout the EEN 
treatment. We believe that the combination of a convincing attitude of the doctor, a close 
follow-up by the dietician and a polymeric nutritional drink is the best formula to achieve 
successful EEN treatment. 
A particularly noteworthy finding was the good clinical response in the two UC patients (one 
also had achieved endoscopic response with lower values of SES-CD and F-calprotectin). It is 
extremely difficult to find reports on UC and EEN treatment189. If the new nomenclature 
according to Cleynen et al is implemented28, speculation could take place as to whether patients 
with Crohn colitis would have any advantage of EEN treatment.  
In this pilot study, we additionally investigated the CMCP at onset and after completion of 
induction of remission in six patients (five with CD and one with IBD-U). We found no 
significant change in expression of any of the 14 cytokines. Nevertheless, in individual patients 
decreases and increases were measured in the regulatory cytokines TGF-β1, CSF-2 and in the 
anti-inflammatory cytokine IL-10. Moreover, decreases were seen in most of the pro-
inflammatory cytokines studied. The expression of the known pro-inflammatory cytokine IL-
12β was upregulated in four patients and only one showed a decrease. Still, when we compared 
the IBD patients with the non-IBD controls, significantly higher values of IL-12β and IL-23α 
were observed in the IBD patients. These cytokines play an important role in the pathogenesis 
of CD190. There are only a few reports on the CMCP after EEN treatment. In a pediatric report 
of 29 children, of whom 17 were treatment-naive, Fell et al found a significant decrease in 
mucosal pro-inflammatory cytokines (measured with PCR) that was associated with clinical 
remission and macroscopic and histological healing191. Their results are partly in line with our 
finding of an increased expression of TGF-β1 after EEN and a higher cytokine expression in the 
IBD patients compared with the non-IBD controls. Yamamoto et al. investigated the CMCP 
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(five cytokines) with ELISA (enzyme-linked immunosorbent assay). Twenty-eight adult CD 
patients completed 4 weeks of an elemental formula. The authors demonstrated that mucosal 
concentrations of TNF-α, IL-1β, IL-6, IL-8 and IL1 receptor antagonists normalized after 
treatment. They also investigated CMCP in healthy controls. Their finding is consistent with our 
findings and those of Fell et al, where significantly higher levels were noted in IBD patients 
compared with healthy controls. One study investigated mucosal cytokines in biopsies of adult 
UC patients (n=20), and CD patients (n=35) in two colonic sites (a non-inflamed site and an 
inflamed site) and in healthy controls (n=54)192. They used PCR and found several cytokines 
augmented in inflamed biopsies compared with normal biopsies. They concluded that 
specimens with UC and CD show different independent cytokine profiles, suggesting that this 
knowledge is important in the development of personalized therapies. The individual pattern of 
the cytokine expression in our study may reflect the CD patients’ diversity in immunological 
phenotype28, 193. To conclude, we found EEN to be a highly effective treatment, and believe that 
an intense engagement between the patients and their physicians and dieticians will increase the 
probability that the patients will adhere to the treatment. The mode of action is still not clear and 
believed to be highly complex with immunological and microbial interactions. Nonetheless, a 
better understanding of the role of both anti-inflammatory and regulatory cytokines as well as 
temporal aspects requires further studies. 
 
 In the EEN study, we planned to investigate the mucosal cytokine profiles and connect the 
immunological results to the mucosal microbiom, investigated by whole genome sequencing. 
Unfortunately, it was a delay in the sequencing, and the results are still not ready. I believe that 
there is need for bigger studies that explore and connect the mucosal immunology with the 
mucosal microbiom in order to understand the mode of action of EEN.  
 
 Practical matters: If I were to do the study again, I would involve a biomedical scientist from 
the start. How to handle the material in the best way is an exclusive knowledge, and a 
biomedical scientist is the one who knows. Things became unnecessarily complicated when it 
comes to these matters. 
 
 About writing articles and how to please supervisors and reviewers: the learning process of 
writing is fun, challenging and at times frustrating. The manuscript may return with the 
supervisor’s different opinions, or with the reviewer’s wish that you have to add so much that 
you have to overstep the word limit. Even if it sometimes was difficult to deal with comments 
and different opinions, I still feel that the review is a valuable tool for the final result.  
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6 ETHICAL REFLECTIONS 
All studies were approved by the local Ethics Committee in Stockholm, Sweden. All patients 
over 15 years were informed and gave written consent, and if the child was younger than 15 
years, informed written consent was obtained from the parents. Our studies were performed in 
accordance with the Helsinki Declaration, where children are considered as a vulnerable 
group194.  
“Medical research with a vulnerable group is only justified if the research is 
responsive to the health needs or priorities of this group and the research cannot 
be carried out in a non-vulnerable group. In addition, this group should stand to 
benefit from the knowledge, practices or interventions that result from the 
research” 
A distinct ethical reflection is always important in the context of research in general, and in 
pediatric research in particular, due to the fact that children belong to a vulnerable group. 
Nevertheless, pediatric research is important because results from adult research may not 
always be applicable to children. Subsequently, not conducting pediatric research could be 
considered unethical because this might be followed by an inferior healthcare for children. 
A quite complicated ethical application is inevitable early in the research process. Instead of just 
thinking of it as problematic, it can be used as a help to define the project and balance the 
possible disadvantage for the patient with the importance of the results. Next question is for 
whom the research will be beneficial; for the subject, an extended group of patients, the 
community or the researcher? These questions are of immense importance, and clear answers 
are needed before the patients are involved.  
The children in my projects have been subject to at least one extra endoscopy examination in 
general anesthesia with additionally blood sampling that we usually not perform in the ordinary 
clinical setting. Further, we tried GMA as a remission treatment which is a non-validated 
method for induction of remission. As a researcher, a conversation with the child and the 
parents concerning the implication of participation in the studies have been important, both for 
the subject and for myself. I have given very clear information that the outcome of the treatment 
is uncertain, and that it entails discomfort to go through an extra endoscopy with bowel 
preparation. In the EEN study the patients received the same treatment as they would have 
received in the clinical setting. Nevertheless, many children decided to participate. I believe that 
it is crucial that the child feels secure and understand what the participation in the study means, 
and that he or she feels free to leave the study without the feeling of making the doctor sad or 
risking an inferior care in the future. The most common answer to my question why they 
wanted to participate in the studies, was that they wanted to contribute to the knowledge of IBD 
for the sake of science. 
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7 CONCLUSIONS  
 
 In the IFX study, we found that only one third of the children on IFX maintenance treatment 
were in clinical and biochemical remission, and that s-IFX was significantly higher during 
remission compared with active disease. A strong correlation was found between ATI and active 
disease.  
 GMA and mesalazine were found to be a safe and effective treatment as an induction of 
remission in children with newly onset IBD. It seems plausible to speculate that the decreases 
seen in mucosal cytokines after treatment may explain the observed clinical efficacy. 
  
 EEN was an effective treatment in all our patients, also in the two patients with UC. The patients 
completed the treatment without a nasogastric tube and without side effects. Additionally, a 
change in the mucosal cytokine profile after induction of remission with EEN was observed. 
 
 
 By investigate the CCRs, we found a possibly prognostic marker for UC and CD. We suggest 
that it would be valuable to further explore the use of CCRs on blood leukocytes as a diagnostic 
tool.  
 
 By investigating the cytokine profiles in mucosal biopsies, we have extended the knowledge of 
immunological phenotypes in children with IBD.  
 
 We think that an active approach must be applied in the care of children with IBD to achieve and 
maintain remission.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA  
Crohns sjukdom (CD) och ulcerös kolit (UC) utgör tillsammans gruppen kronisk 
inflammatorisk tarmsjukdom, som ofta benämns IBD, efter engelskans ”inflammatory bowel 
disease”. I Sverige är ca 0,65 % av befolkningen drabbad, och ca 10-20 % av de drabbade 
insjuknar under barndomen. I Sverige är sjukdomen således ganska vanlig, och IBD är generellt 
sett vanligare i den rika delen av världen än i den fattiga. 
Uppkomstmekanismerna till IBD är okända. Trots mycket forskning i ämnet är det fortfarande 
oklart varför man insjuknar i IBD, men en kombination av arv, immunologiska faktorer och 
miljöfaktorer tros samverka. 
Symtomen är liknande för UC och CD med buksmärtor, (blodiga) diarréer, illamående, trötthet, 
dålig ork, uppblåst mage, viktnedgång och för barn ibland dålig tillväxt. Man kan även vid CD 
få fistelgångar mellan tarm och hud, anala bölder eller trånga partier i tarmen. Andra organ i 
buken som lever och gallvägar kan påverkas liksom symtom utanför magtarmkanalen kan 
uppstå som hudutslag, ledvärk, ögonbesvär och munsår. 
Sjukdomsförloppet kännetecknas av att symtomen kommer och går, och när man får mycket 
symtom kallas de för att man får skov. Barn har oftare ett aggressivare förlopp än vuxna, och 
eftersom barnaåren är en viktig och kort tid i livet när tillväxt, skola, sociala kontakter och 
självbild skall utvecklas, bör skov undvikas, varför de allra flesta barn har en pågående 
behandling för att förhindra nya inflammationsutbrott, s.k. underhållsbehandling. 
Om barnet trots allt får ett skov, vilket är ganska vanligt trots underhållsbehandling, behandlar 
man med en s.k. remissions behandling för att dämpa inflammationsutbrottet, och inte sällan 
består denna behandling av höga doser kortison, vilket kan resultera i allvarliga biverkningar på 
både kort och lång sikt som t.ex. viktuppgång, svår acne, hudbristningar, psykisk oro, magont, 
sömnlöshet, högt blodtryck och benskörhet.  
Alla barn som misstänks ha IBD lämnar blodprover och genomgår en gastroskopi och 
koloskopi där små vävnadsprover tas på många ställen i magsäcken och tarmen och undersöks i 
mikroskop av en patolog som kan finna särskilda karaktäristika tillhörande de olika 
sjukdomarna.  
I studie 1 undersökte vi hur ett exklusivt, dyrt läkemedel; infliximab (IFX) (Remicade®, 
Inflectra®, Humira®) fungerar hos barn som behandlas med IFX som underhållsbehandling. 
Det är ett biologiskt aktivt läkemedel som består av antikroppar mot ett inflammationsämne (en 
cytokin) som heter TNF-α, vilket bildas vid inflammation. IFX hämmar TNF-molekylen så den 
inte kan skapa mer inflammation. Att IFX är biologiskt aktivt innebär tyvärr att kroppen kan 
reagera mot läkemedlet och uppfatta det som en fiende som skall bekämpas. Detta gör att det är 
svårt att förutse hur mycket läkemedel en enskild patient behöver, samt att man kan få en 
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allergisk reaktion när man får sin IFX-dos. Vanligtvis får patienterna IFX var fjärde till åttonde 
vecka som infusion på mottagningen. Vi ville studera hur mycket IFX IBD-patienterna har kvar 
i blodet när de kom för att få sin nästa infusion (dalvärde). Vi kontrollerade sänka och CRP, och 
de fick fylla i formulär hur de mådde (klinisk scoring) Vi fann att en tredjedel av patienterna 
hade aktiv inflammation och inte mådde bra trots behandlingen, och att de som utvecklat 
antikroppar mot IFX inte hade något läkemedel kvar i blodet. Alla dessa var i aktiv sjukdom. 
I studie II och V utförde vi två kopplade studier som tidigare inte gjorts; barn med som 
nyinsjuknat i kolit (tjocktarmsinflammation) fick behandling med granulocyt monocyt apheres 
(GMA), vilket vanligtvis ges som en sista utväg vid behandlingsvikt när man provat allt annat 
och inget fungerar. GMA är inget läkemedel utan jämförs bäst med dialys, där blodet renas från 
aktiverade inflammations celler som cirkulerar i blodbanan som annars skulle vandra ner till 
tjocktarmen och skapa inflammation. Tolv barn och ungdomar över 12 år, fick 10 behandlingar 
under 5 veckor samt en mild tilläggsbehandling med meslazin (studie II). Barnen genomgick en 
kontroll koloskopi ca tre månader efter den tionde och sista GMA behandlingen. Vid den första 
koloskopin och kontroll koloskopin togs även vävnadsprover i tjocktarmen för undersökning av 
14 olika inflammationsämnen (cytokiner, undersöks med en avancerad teknik som heter PCR) 
för immunologisk testning (studie V) Vi fick resultat på före-efter GMA på sju barn. Vi fann 
vid kontrollen att 9 av 12 barn var helt bra eller tydligt bättre i sin tarmslemhinna, och att 8 av 
12 barn tyckte de kände sig helt bra (klinisk remission) samt tydliga nedgångar i 
inflammationsprover i blodet. Vid undersökning av cytokinerna i tarmslemhinnan på sju barn 
sågs en tydlig nedgång i sju olika cytokiner och mycket högre nivåer av cytokiner sågs mellan 
sjuka och sex friska kontroller. Vi spekulerar i att nedgångarna i tarmslemhinnan förklarar det 
goda behandlingssvaret. 
I studie III undersökte vi små ämnen i blodet som heter chemokin-receptorer med hjälp av en 
avancerad teknik som kallas för flödescytometri. Chemokin-receptorer är en slags mycket små 
proteiner som fungerar som adresslappar på inflammationsceller, vilket gör att de guidar 
inflammationscellerna dit de ska (platsen för inflammation). Vi undersökte chemokin-receptor 
landskapet på barn med UC, CD och friska kontroller. En statistisk algoritm utifrån chemokin-
receptor mönstret på fyra olika vita blodkroppar utarbetades varpå vi kunde särskilja UC från 
CD. Detta är en pilotstudie för att utveckla en prognostisk markör då vi i ca 10 % av fallen har 
svårt att korrekt diagnostisera UC från CD, viket gör att vissa patienter kan få en felaktig eller 
sämre behandling än om de haft rätt diagnos från början. 
I studie IV behandlade vi 12 barn nydiagnostiserade med CD och behandlade dem med 
flytande kostbehandling, s.k. exklusiv enteral nutritionsbehandling (EEN) vilket innebär att 
barnet enbart dricker näringsdrycker (Fortimel Energy®) under sex veckor utan annan föda eller 
mediciner. Detta är den gängse behandlingen för barn med CD i Europa och USA, men i många 
fall lyckas inte patienterna genomgå behandlingen eller ens få chansen utan behandlas istället 
med höga doser kortison. Tidigare studier har visat att behandlingen är biverkningsfri och läker 
tarmen bättre än kortison. Vi ville undersöka hur våra patienter svarade på behandlingen, samt 
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hur cytokinerna såg ut i tarmslemhinnan före och efter behandling. Elva barn genomförde sex 
veckors behandling, ett barn genomförde fyra veckor. Alla barn hade mycket god effekt av 
behandlingen och tydliga nedgångar sågs i inflammationsprover i blodet, kliniskt status och 
läkning i tarmslemhinnan. Cytokinprofilerna visade inga tydliga (signifikanta) nedgångar i hela 
gruppen med vid analys på de enskilda patienterna sågs nedgångar i de flesta cytokinerna men 
även en del uppgångar i de cytokiner som reglerar eller hämmar inflammationen. Vi bedömer 
att ett stort engagemang från doktor och dietist med tät uppföljning samt att använda den mest 
välsmakande näringsdrycken så barnen slipper sond, är nyckeln till en framgångsrik EEN 
behandling. Vi tror att EEN ger effekter i inflammationsmönstret i tarmen, men fler studier som 
undersöker detta behöver göras för att bättre förstå varför EEN är en effektiv behandling. 
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